[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 853
1. Pollefliet C, Peters K, Janssens A, Luijks A, Van Bouwel E, Van Marck E, Germonpre P: Endobronchial lipomas: rare benign lung tumors, two case reports. J Thorac Oncol; 2009 May;4(5):658-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial lipomas: rare benign lung tumors, two case reports.
  • Endobronchial lipoma is a rare benign lung tumor.
  • We discuss the epidemiology, difficulties in establishing the diagnosis, and the management of this rare condition.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Lipoma / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19395910.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Zheng QF, Dong B, Sun Y, DU H, Xiong HC, Wu N, Chen JF, Sun L, Ao J, Li JY, Ji JF, Yang Y: [Expression of TR4-associated protein in non-small cell lung cancer]. Beijing Da Xue Xue Bao; 2007 Oct 18;39(5):472-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of TR4-associated protein in non-small cell lung cancer].
  • OBJECTIVE: To investigate the expression and significance of TR4-associated Protein (TRA16) in human non-small cell lung cancer (NSCLC) tissues.
  • METHODS: Immunohistochemistry (IHC) and tissue array were employed to investigate the expression of TRA16 in NSCLC cases of different pathological types, benign lung lesions and normal lung tissues.
  • RESULTS: The abundant expression of TRA16 was observed in nucleus and/or cytoplasm of NSCLC cells with a positive expression rate of 88.64%, whereas normal lung tissue and benign lung tumor rarely expressed TRA16 protein.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Nuclear Proteins / metabolism. Repressor Proteins / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940562.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NR2C2AP protein, human; 0 / Nuclear Proteins; 0 / Repressor Proteins
  •  go-up   go-down


3. Stojsić J, Milenković B, Radojicić J, Percinkovski M: [Alveolar adenoma -- a rare lung tumour]. Srp Arh Celok Lek; 2007 Jul-Aug;135(7-8):461-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alveolar adenoma -- a rare lung tumour].
  • INTRODUCTION: Alveolar adenoma belongs to the group of benign epithelial tumours.
  • CONCLUSION: Alveolar adenoma is a rare benign lung tumour, most frequently presented as a solitary pulmonary nodule.
  • After complete surgery, the tumour neither relapses nor malignantly alters.
  • [MeSH-major] Adenoma / diagnosis. Lung Neoplasms / diagnosis. Solitary Pulmonary Nodule / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929540.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


Advertisement
4. Rai SP, Patil AP, Saxena P, Kaur A: Laser resection of endobronchial hamartoma via fiberoptic bronchoscopy. Lung India; 2010 Jul;27(3):170-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endobronchial hamartoma is a rare benign tumor of lung that may present with symptoms of airway obstruction with wheezing, stridor, recurrent pneumonia or atelectasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20931040.001).
  • [ISSN] 0974-598X
  • [Journal-full-title] Lung India : official organ of Indian Chest Society
  • [ISO-abbreviation] Lung India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2946723
  • [Keywords] NOTNLM ; Diode laser / endobronchial hamartoma / fiberoptic bronchoscope / laser resection
  •  go-up   go-down


5. Fatima S, Ahmed Z, Azam M: Benign metastasizing leiomyoma. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):802-4
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign metastasizing leiomyoma.
  • Benign metastasizing leiomyoma (BML) is a rare condition, affecting predominantly reproductive-age females with uterine leiomyomata and is most often associated with multiple benign-appearing smooth muscle tumors in lungs.
  • Histopathology of one of the pleura-based nodules revealed a neoplasm composed of interlacing fascicles of spindle cells with uniform nuclei.
  • The tumor cells were positive for alpha-smooth muscle actin and negative for CD34 immunohistochemical stain.
  • [MeSH-major] Leiomyoma / diagnosis. Lung Neoplasms / secondary. Pleural Neoplasms / secondary. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Actins / analysis. Adult. Antigens, CD34 / analysis. Female. Histocytochemistry. Humans. Hysterectomy. Immunohistochemistry. Microscopy. Pleural Effusion / diagnosis. Radiography, Thoracic. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045423.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Antigens, CD34
  •  go-up   go-down


6. Smati B, Ismail O, Boudaya MS, Baccari S, Djilani H, Mestiri T, El Mezni F, Gharbi L, Kilani T: [Huge benign lung tumor in a female smoker]. Rev Pneumol Clin; 2005 Dec;61(6):379-81
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Huge benign lung tumor in a female smoker].
  • [Transliterated title] Tumeur de 5 cm chez une femme fumeuse.
  • Pulmonary sclerosing hemangioma is a rare, slow-growing, benign tumor.
  • Intraoperative pathology analysis revealed the benign nature of the tumor.
  • The final pathological conclusion was sclerosing hemangioma of the lung.
  • Pulmonary sclerosing hemangioma is a parenchymal tumor of the lung.
  • Surgery is always required for cure, and must be associated with lymph node dissection for large tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16449928.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Nakamura H, Adachi Y, Arai T, Miwa K, Haruki T, Fujioka S, Taniguchi Y: A small alveolar adenoma resected by thoracoscopic surgery. Ann Thorac Surg; 2009 Mar;87(3):956-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alveolar adenoma (AA) is a rare lung benign tumor originated from type II pneumocytes.
  • It presents as a well-defined nodule in clinical images, but is difficult to differentiate from early-stage lung cancer.
  • We treated a 58-year-old woman with a small-sized AA measuring 8 x 6 mm in the upper lobe of the left lung by performing a thoracoscopic resection.
  • There have been no reported cases of recurrence after a resection of AA, but a subsequent increase in such cases is expected, and we believe that it is necessary to understand the characteristics of this typical benign lung tumor.
  • [MeSH-major] Adenoma / surgery. Lung Neoplasms / surgery. Thoracoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19231437.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


8. Oshikiri T, Morita T, Fujita M, Miyasaka Y, Senmaru N, Yamada H, Kaji N, Kondo S: Resection of lung metastasis from gallbladder carcinoma: immunohistochemistry of RCAS1 and CD8+T cells in primary and metastatic tumors. Cancer Lett; 2006 Jun 8;237(1):115-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of lung metastasis from gallbladder carcinoma: immunohistochemistry of RCAS1 and CD8+T cells in primary and metastatic tumors.
  • We examined a patient with resectable gallbladder cancer with associated lung metastasis.
  • A 64-year-old female patient, diagnosed with gallbladder cancer and a solitary benign lung tumor by imaging, was subjected to extensive cholecystectomy and extrahepatic bile duct resection.
  • After one year, a follow-up CT indicated enlargement of the lung tumor; video-assisted right middle lobectomy was then performed.
  • The lung tumor was diagnosed as a metastasis derived from the gallbladder cancer by pathology and immunohistochemistry.
  • Expression of RCAS1, an independent unfavorable prognostic indicator in gallbladder cancer, was observed in both the gallbladder and lung tumors.
  • However, infiltration of CD8+T cells was only seen in the lung metastatic tumor.
  • [MeSH-major] Adenocarcinoma, Papillary / metabolism. Antigens, Neoplasm / metabolism. CD8-Positive T-Lymphocytes / pathology. Gallbladder Neoplasms / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Lymphocytes, Tumor-Infiltrating / pathology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039043.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / EBAG9 protein, human
  •  go-up   go-down


9. Situ DR, Long H, Ma GW, Lin ZC, Yun JP, Rong TH: [Diagnosis and therapeutics of 24 cases of pulmonary sclerosing hemangioma]. Ai Zheng; 2008 Aug;27(8):861-5
Genetic Alliance. consumer health - Hemangioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapeutics of 24 cases of pulmonary sclerosing hemangioma].
  • BACKGROUND & OBJECTIVE: Pulmonary sclerosing hemangioma (PSH) is an uncommon benign lung tumor.
  • The study was to investigate the clinical features, diagnosis, treatment, and prognosis of PSH in order to promote the recognition of this disease.
  • The clinical features, diagnosis, treatment, and prognosis were summarized.
  • Eight patients underwent lobectomy, 13 underwent wedge resection, two underwent tumor resection and one underwent segmentectomy.
  • Thus, accurate diagnosis of PSH before operation is difficult.
  • [MeSH-major] Pneumonectomy / methods. Pulmonary Sclerosing Hemangioma / diagnosis. Pulmonary Sclerosing Hemangioma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18710622.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Hu WD, Liao MY, Chen JK: [Clinical analysis of solitary pulmonary nodule measuring less than 10 mm]. Ai Zheng; 2006 Feb;25(2):217-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Lung cancer is a malignant disease with high incidence and mortality, and its prognosis is to large degree determined by early diagnosis and treatment.
  • X-ray chest film and computed tomography (CT) are important means to discover and diagnose lung cancer.
  • The differences between benign and malignant lesions were compared.
  • Imaging features of SPN of lung cancer were summarized.
  • RESULTS: Of the 102 cases of SPN measuring less than 10 mm, 66 (64.7%) were benign lesions, 25 (24.5%) were primary lung cancer, and 11 (10.8%) were metastatic lung cancer.
  • The benign lesions included inflammatory pseudotumor, benign tumor, lung tuberculosis, and so on.
  • Primary lung cancers, including 6 advanced cases (stage IIA and higher stage), had several radiological features different from benign nodules, such as ill-defined margins, speculation, bronchus or vessel involvement.
  • Also, the enhanced CT value was higher in malignant nodules than in benign nodules except inflammation pseudotumor.
  • The SPNs of metastatic lung cancer had similar radiologic features to those of primary lung cancer.
  • CONCLUSION: SPNs measuring less than 10 mm are mainly composed of benign lung tumor and primary lung cancer.
  • [MeSH-major] Lung Neoplasms. Solitary Pulmonary Nodule
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / secondary. Female. Granuloma, Plasma Cell / pathology. Granuloma, Plasma Cell / radiography. Humans. Lung Diseases / pathology. Lung Diseases / radiography. Male. Middle Aged. Retrospective Studies. Smoking. Tomography, X-Ray Computed / methods. Tuberculosis, Pulmonary / pathology. Tuberculosis, Pulmonary / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16480590.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Kang MW, Han JH, Yu JH, Kim YH, Na MH, Yu JH, Lim SP, Lee Y, Kim JH, Kang DY, Kim JO: Multiple central endobronchial chondroid hamartoma. Ann Thorac Surg; 2007 Feb;83(2):691-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign neoplasm of the lung is rare, and pulmonary hamartoma is the most common form of benign neoplasm of the lung.
  • Reports of multiple endobronchial chondroid hamartomas are rare in the literature, and the awareness of this form of benign disease is important in the differential diagnosis of pulmonary neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258021.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


12. Ozbudak IH, Dertsiz L, Bassorgun CI, Ozbilim G: Giant cystic chondroid hamartoma of the lung. J Pediatr Surg; 2008 Oct;43(10):1909-11
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cystic chondroid hamartoma of the lung.
  • Pulmonary hamartoma composed of an abnormal mixture of mesenchymal elements is the most common benign neoplasm in the lung.
  • Chest computed tomography revealed a heterogeneous mass filling the middle and the lower lobes of the right lung.
  • We believe this is the first case of 'giant cystic chondroid hamartoma of the lung' described in childhood.
  • We suggest that giant cystic pulmonary hamartoma should be included in the differential diagnosis of large intrathoracic masses in children.
  • [MeSH-major] Cysts / surgery. Hamartoma / surgery. Lung Diseases / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adipose Tissue / pathology. Calcinosis / pathology. Calcinosis / radiography. Calcinosis / surgery. Cartilage / pathology. Child. Diagnosis, Differential. Epithelium / pathology. Humans. Incidental Findings. Lung Neoplasms / diagnosis. Male. Thoracotomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926231.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Matsuda E, Okabe K, Kobayashi S, Hirazawa K, Yamamoto H, Tao H, Murakami T, Sugi K: [Pulmonary hamartoma associated with lung cancer]. Kyobu Geka; 2010 Sep;63(10):875-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary hamartoma associated with lung cancer].
  • Pulmonary hamartoma is most common benign tumor of the lung and is not recognised as having a character of malignant transformation.
  • So, longtime radiological observation is not uncommon for patients with diagnosis of pulmonary hamartoma from computed tomography (CT) finding.
  • Although pulmonary hamartoma does not transform to malignancy, high frequency of coexistence hamartoma and lung cancer has been reported.
  • We experienced 14 cases of resected pulmonary hamartoma, and 3 of them had lung cancer, showing that 21.4% of pulmonary hamartoma coexisted with lung cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Hamartoma / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845697.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Roberge D, Hickeson M, Charest M, Turcotte RE: Utility of total body FDG PET/CT imaging in the initial staging of soft-tissue sarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):10531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10531 Background: Soft-tissue sarcoma spreads predominantly to the lung.
  • Ewing's sarcoma, rhabdomyosarcoma and GIST tumors were excluded as were patients imaged for follow-up, response assessment or recurrence.
  • In 21% of cases, the primary tumor had been removed by excisional biopsy or unplanned excision prior to staging.
  • 97% of the previously unresected primary tumors were FDG avid (SUV ≥ 2).
  • 81% of tumors were high-grade (FNCLCC Grade 2-3).
  • The primary tumor was stage T2b in 68% of cases.
  • Two incidental benign parotid tumors were found.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963909.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Alaoui-Jamali MA Sr, Gupta A, Szarek WA, Bismar TA, Gheorghe R, Schipper HM: A novel selective therapeutic targeting heme oxygenase-1 revealed a potent antimetastatic activity in androgen-refractory human prostate cancer models. J Clin Oncol; 2009 May 20;27(15_suppl):e16090

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite a significant improvement in the overall survival attributed in part to early detection and introduction of novel therapeutic modalities, many cancer patients at primary diagnosis present advanced disease or experience recurrence of the cancer.
  • In this study, we identified heme oxygenase 1 (HO-1) to be significantly upregulated in epithelial PCA cells, but not in surrounding stromal cells, from hormone refractory prostate cancer cases compared to hormone-responsive prostate cancer and to benign tissues.
  • Specifically, inhibition of HO-1 gene in androgen-independent and highly invasive prostate cancer cells, PC3M, decreased HO-1 activity, oxidative stress, MAPKs activation, cell proliferation, and cell migration and invasion in vitro, as well as inhibition of prostate tumor growth and lymph nodes and lung metastases in vivo.
  • OB-24 selectively downregulates HO-1 activity, oxidative stress, and significantly inhibits cell proliferation in vitro and tumor growth and lymph node/lung metastases in vivo.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963085.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Davidson JA, Wong V, Fraser R, Hirsh V: Comparison of primary tumor maximal standardized uptake value (SUV<sub>max</sub>) on preoperative [18F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) and histological subtype in patients with non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of primary tumor maximal standardized uptake value (SUV<sub>max</sub>) on preoperative [18F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) and histological subtype in patients with non-small cell lung cancer (NSCLC).
  • The SUV<sub>max</sub> is a semiquantitative measure of metabolic activity that can distinguish benign from malignant tissue but published data are conflicting regarding its ability to discriminate between major histological subtypes.
  • The SUV<sub>max</sub> values for each histological subtype, along with primary tumor sizes, were compared using F test and t-test analyses.
  • RESULTS: The 15 patients with SC and 5 with LC histology were found to have significantly greater preoperative SUV<sub>max</sub> values than the 19 patients with AC (mean 12.7 and 17.2 vs. 9.4, respectively, P < 0.05), despite the fact that no significant differences in tumor size were observed between histological subtypes.
  • CONCLUSIONS: These data suggest that SC pulmonary tumors have significantly greater uptake on PET/CT than AC tumors.
  • This finding may be helpful in the future when sufficient tissue cannot be obtained for pathological diagnosis or to identify the predominant pathology of mixed tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963356.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Xie L, Chen X, Qian X, Wei J, Ding Y, Zhang C, Liu B: Cell-free miR-10b and miR-21 as diagnostic biomarkers for malignant effusions. J Clin Oncol; 2009 May 20;27(15_suppl):11035

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11035 Background: Numerous studies have proved the roles of tissue microRNAs (miRNAs) as biomarkers in cancer diagnosis.
  • Cell-free miRNAs from plasma or serum have been shown to be good biomarkers in the diagnosis of cancers.
  • Here we tried to explore the potential application of cell-free miRNAs as diagnostic biomarkers to discriminate malignant effusions from benign.
  • METHODS: To obtain a molecular signature for malignant effusions, a stem-loop real-time PCR was adopted to measure the expression of 23 tumor-related miRNAs.
  • After a pre-screening for discarding low amount miRNAs in 10 samples (5 benign/5 malignant) and a proper internal control was identified, the expression levels of 7 miRNAs were further compared among 74 malignant effusion samples (35 gastric cancer-related ascites and 39 lung cancer-related plural effusions) and 30 benign effusions. miRNAs specifically associated with malignant effusions were derived from a training group (20 malignant/10 benign) and tested in a validation group (54 malignant/20 benign).
  • All samples were confirmed by both pathological and clinical diagnosis.
  • The expression of miR-10b was significantly different between benign and malignant effusions (P< 0.001).
  • CONCLUSIONS: In the present study, we demonstrated that cell-free miRNA can serve as a novel diagnostic biomarker in distinguishing malignant from benign effusions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964012.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Tamura Y, Kushibe K, Tojo T, Takahama M, Kimura M, Taniguchi S: Intralobar sequestration presenting as a large intrapulmonary hematoma and massive hemothorax. Jpn J Thorac Cardiovasc Surg; 2006 Oct;54(10):437-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • His chest computed tomography (CT) scan revealed a large intrapulmonary hematoma and massive hemothorax, mimicking a benign lung tumor ruptured into the pleural cavity.
  • We should keep the possibility of this anomaly in mind if a patient with hemoptysis has a cystic lung tumor and hemothorax on CT scan.
  • [MeSH-major] Bronchopulmonary Sequestration / diagnosis. Hematoma / etiology. Hemothorax / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Lung Neoplasms / diagnosis. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17087324.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Li W, Ni Y, Tu Z, Wu S, Wu Z, Zheng S: Study of telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer and its clinical significance. Eur J Cardiothorac Surg; 2009 Sep;36(3):460-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer and its clinical significance.
  • OBJECTIVE: To detect telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer (NSCLC) and to evaluate its clinical value.
  • METHODS: From July 2005 to May 2007, 167 pleural lavage fluid specimens were obtained from 135 patients with NSCLC and 32 patients with benign lung tumour during operation.
  • Telomerase activity was negative in all 32 patients with benign lung tumour.
  • There was a significant relationship between telomerase activity and pleural extension, T level, N level as well as the clinical TNM (tumour, node, metastasis) stage of lung cancer.
  • CONCLUSION: Telomerase activity is a useful adjunct for cytological method in the diagnosis of pleural micro-metastasis and was related to prognosis in a patient with NSCLC.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / enzymology. Lung Neoplasms / enzymology. Pleural Cavity / enzymology. Pleural Neoplasms / secondary. Telomerase / metabolism
  • [MeSH-minor] Adult. Aged. Clinical Enzyme Tests / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Therapeutic Irrigation

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502078.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


20. Toporcer T, Belák J, Böör A, Kudlác M, Lakyová L, Radonak J: [Giant solitary fibrous tumor of the pleura--case report]. Rozhl Chir; 2009 Mar;88(3):97-102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant solitary fibrous tumor of the pleura--case report].
  • [Transliterated title] Obrovský solitárny fibrózny tumor pleury--kazuistika.
  • Solitary fibrous tumors of the pleura are rare malignant pathological findings, accounting for only 5% of all pleural neoplasms.
  • Her chest x-ray and CT examination suggested a large cystoid lesion in the right hemithorax, with extensive dystelectasis of the right lung lobe.
  • Functional pulmonary examination confirmed severe gas transfer dysfunction, with diffusion lung capacity of 47% of the normal.
  • The authors performed right-sided thoracotomy and removed an encapsulated solid tumor measuring 24 x 16 x 13.5 cm and weighting 2850 grams from the thoracic cavity.
  • Benign solitary fibrous tumor was diagnosed on histology.
  • The aim of the study is to draw attention to this tumorous disorder of the pleura - the solitary fibrous tumor.
  • [MeSH-major] Pleural Neoplasms / pathology. Solitary Fibrous Tumor, Pleural / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526938.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] slo
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


21. Haruki T, Nakamura H, Taniguchi Y, Miwa K, Adachi Y, Fujioka S: Pulmonary mucinous cystadenoma: a rare benign tumor of the lung. Gen Thorac Cardiovasc Surg; 2010 Jun;58(6):287-90
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary mucinous cystadenoma: a rare benign tumor of the lung.
  • This tumor is histologically characterized by a benign proliferation of mucin-producing epithelial cells and bulky mucin inside the tumor.
  • We present the case of a 71-year-old woman with increasing mass shadow on chest radiography who underwent tumor resection by video-assisted thoracic surgery.
  • The tumor was diagnosed histologically as PMCA.
  • [MeSH-major] Cystadenoma, Mucinous. Lung Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20549459.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Gómez García I, Molina Burgos R, Fernández Fernández E, Palacio España A, González Chamorro F, Alvarez E, Conde Someso S: [Myofibroblastic tumor of bladder]. Actas Urol Esp; 2005 Jun;29(6):611-4
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myofibroblastic tumor of bladder].
  • [Transliterated title] Tumor miofibroblástico de vejiga.
  • The myofibroblastic tumor, is a mesenchymal benign tumor of exceptional character, being its localization but habitual it is the lung; while its appearance in the bladder, is exceptional, not existing but of 100 published cases, of this tumor type in the bladder.
  • This tumor type that clinic and radiologics, behave as a wicked tumor.
  • The pathological diagnosis is complex, due to its similarity with the sarcomas, being necessary to appeal to the inmunohistochemics for a I diagnose of certainty.
  • We present a new case of this neoplasm, carrying out a wide bibliographical revision.
  • [MeSH-major] Granuloma, Plasma Cell / diagnosis. Urinary Bladder Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16092689.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


23. Sousa V, Carvalho L: [Glomic tumor: presentation of an infrequent case]. Rev Port Pneumol; 2006 May-Jun;12(3):269-74
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Glomic tumor: presentation of an infrequent case].
  • [Transliterated title] Tumor glómico do pulmão: Apresentação de um caso pouco frequente.
  • They are more frequent in the subungueal region and rare in the lung.
  • Glomic tumours are generally benign.
  • They should be classified as glomic tumor, glomangioma and glomangiomioma according to the relative abundance of glomic cells and of the vascular and muscular components.
  • The differential diagnosis of glomic tumours of the lung includes the carcinoid, hemangioperycitoma, smooth muscle tumours (epithelioid leyomioma) and the paraganglioma.
  • [MeSH-major] Glomus Tumor / diagnosis. Lung Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967176.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


24. Rego A, Amado J, Esteves I, Almeida J, Furtado A, Couceiro A, Moura e Sá J: [Endobronchial granular cell tumor - what approach to take]. Rev Port Pneumol; 2006 Jul-Aug;12(4):463-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endobronchial granular cell tumor - what approach to take].
  • [Transliterated title] Tumor de células granulares endobrônquico - Como abordamos?
  • Granular cell tumor is a mesenchymal neoplasm almost always benign, with tendency to recurrence.
  • Its occurrence in the lung is extremely rare.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Bronchial Neoplasms / therapy. Granular Cell Tumor / diagnosis. Granular Cell Tumor / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969575.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


25. Han B, Jiang G, Wang H, He W, Liu M, Song N: Benign clear cell tumor of the lung. Ann Thorac Surg; 2010 Jun;89(6):2012-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign clear cell tumor of the lung.
  • Clear cell tumor of the lung is a rare benign tumor.
  • The patient underwent a lobectomy for the tumor.
  • The pathologic report supported the diagnosis of clear cell tumor of the lung.
  • [MeSH-major] Lung Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20494071.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


26. Policarpio-Nicolas ML, Covell J, Bregman S, Atkins K: Fine needle aspiration cytology of clear cell "sugar" tumor (PEComa) of the lung: report of a case. Diagn Cytopathol; 2008 Feb;36(2):89-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of clear cell "sugar" tumor (PEComa) of the lung: report of a case.
  • PEComa (clear cell "sugar" tumor) of the lung is a rare benign tumor of the lung probably arising from the perivascular epithelioid cells (PECs).
  • In this case report, the clinical, cytologic and immunohistochemical features clear cell "sugar" tumor of the lung are discussed and compared with the previously published literature.
  • The differential diagnosis and methods for distinguishing the various clear cells lesions in the lung are discussed.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Neoplasms, Connective and Soft Tissue / diagnosis. Neoplasms, Connective and Soft Tissue / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Epithelioid Cells / metabolism. Epithelioid Cells / pathology. Glycogen / metabolism. Humans. Lung / metabolism. Lung / pathology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18181192.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9005-79-2 / Glycogen
  •  go-up   go-down


27. Adachi Y, Kitamura Y, Nakamura H, Taniguchi Y, Miwa K, Horie Y, Hayashi K: Benign clear (sugar) cell tumor of the lung with CD1a expression. Pathol Int; 2006 Aug;56(8):453-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign clear (sugar) cell tumor of the lung with CD1a expression.
  • Reported herein is a case of benign clear cell tumor of the lung in a 60-year-old man.
  • Chest X-ray and CT examination revealed an abnormal nodule with homogenous density and a clear margin in the lower lobe of the left lung.
  • The resected tumor was 13 mm in size, well-circumscribed and was graysh-white on cut surface.
  • Histological examination showed a diffuse growth pattern of polygonal tumor cells with indented and pleomorphic nuclei, and clear abundant cytoplasm with a distinct cell border surrounded by thin-walled vascular spaces and sinusoid-type vessels.
  • In the present case there was focal immunoreactivity for S-100 protein, HMB-45, neuron-specific enolase, cathepsin B and melan A, which are consistent with reported immunohistochemical staining patterns of benign clear cell tumor.
  • Based on these findings, the tumor was diagnosed as a benign clear cell tumor of the lung.
  • Although most clear cell tumors are considered to belong to the family of neoplasms with perivascular epithelioid cell differentiation (PEComas), histogenesis of benign clear cell tumor of the lung has remained unclear.
  • This first report of CD1a expression in this tumor might provide a new insight into its histogenesis and diagnosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Antigens, CD1 / metabolism. Biomarkers, Tumor / metabolism. Lung Neoplasms / pathology. Solitary Pulmonary Nodule / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872440.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD1; 0 / Biomarkers, Tumor; 0 / CD1a antigen
  •  go-up   go-down


28. Sapmaz F, Ergin M, Katrancioglu O, Gonlugur T, Gonlugur U, Elagoz S: Benign metastasizing leiomyoma. Lung; 2008 Jul-Aug;186(4):271-273
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign metastasizing leiomyoma.
  • The patient had no history of neoplasm except a hysterectomy for uterine leiomyoma five years before.
  • Six months after the first presentation, the tumor showed a gradual increase in size; an explorative thoracotomy was performed.
  • The histopathologic examination showed a tumor consisting of well-differentiated spindle-shaped cells with intervening collagen.
  • Multiple pulmonary nodules appeared when the lung was re-expanded by chest tube drainage.
  • In conclusion, uterine leiomyomas can metastasize to various organs, such as lungs, despite having a benign pathologic appearance.
  • [MeSH-major] Leiomyoma / pathology. Lung Neoplasms / secondary. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357490.001).
  • [ISSN] 0341-2040
  • [Journal-full-title] Lung
  • [ISO-abbreviation] Lung
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Sen S, Senturk E, Kuman NK, Pabuscu E, Kacar F: PEComa (clear cell "sugar" tumor) of the lung: a benign tumor that presented with thrombocytosis. Ann Thorac Surg; 2009 Dec;88(6):2013-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PEComa (clear cell "sugar" tumor) of the lung: a benign tumor that presented with thrombocytosis.
  • Perivascular epithelioid cell tumors of the lung are rare, benign neoplasms, usually presenting as a solitary pulmonary nodule on chest roentgenograms.
  • Most lesions are solitary and asymptomatic, and are located within the peripheral lung.
  • This is a case report of a 44-year-old woman who presented with thrombocytosis and solitary pulmonary nodule of the lung, which was removed by a thoracotomy.
  • [MeSH-major] Lung Neoplasms / diagnosis. Perivascular Epithelioid Cell Neoplasms / diagnosis. Thrombocytosis / complications
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Platelet Count. Pneumonectomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19932282.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


30. Langenfeld EM, Bojnowski J, Perone J, Langenfeld J: Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg; 2005 Sep;80(3):1028-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of bone morphogenetic proteins in human lung carcinomas.
  • Bone morphogenetic protein-2 (BMP-2) was recently shown to be expressed in a small sample of lung carcinomas.
  • Studies have suggested that BMP-2 may enhance tumor growth.
  • The present study examined which BMP family members are expressed in non-small cell lung carcinomas (NSCLC).
  • Furthermore, the frequency of BMP-2 overexpression and the types of lung carcinomas expressing BMP-2 were determined.
  • Samples included metastatic NSCLC, benign lung tumors, adenocarcinoma, squamous cell carcinoma, bronchioloalveolar, and neuroendocrine carcinomas.
  • Paired normal lung tissues served as the controls.
  • The BMP-2 was expressed in 41 of 42 NSCLC with minimal expression in normal lung tissue; BMP-2 was expressed 17 fold higher than that of normal lung tissue.
  • The BMP-2 was not significantly expressed in benign lung tumors.
  • The BMP-2 is overexpressed in the majority of human lung carcinomas independent of cell type.
  • [MeSH-major] Bone Morphogenetic Proteins / metabolism. Lung Neoplasms / genetics. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Bone Morphogenetic Protein 2. Bone Morphogenetic Protein 4. Bone Morphogenetic Protein 6. Bone Morphogenetic Protein 7. Carcinoma, Neuroendocrine / genetics. Carcinoma, Neuroendocrine / metabolism. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Growth Differentiation Factor 5. Humans. Transforming Growth Factor beta / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2005 Sep;80(3):1032 [16122480.001]
  • (PMID = 16122479.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91919-01A1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BMP2 protein, human; 0 / BMP4 protein, human; 0 / BMP6 protein, human; 0 / BMP7 protein, human; 0 / Bone Morphogenetic Protein 2; 0 / Bone Morphogenetic Protein 4; 0 / Bone Morphogenetic Protein 6; 0 / Bone Morphogenetic Protein 7; 0 / Bone Morphogenetic Proteins; 0 / GDF5 protein, human; 0 / Growth Differentiation Factor 5; 0 / Transforming Growth Factor beta
  •  go-up   go-down


31. Psaras T, Pantazis G, Steger V, Meyermann R, Honegger J, Beschorner R: Benign meningioma developing late lung metastases: case report and review of the literature. Clin Neuropathol; 2009 Nov-Dec;28(6):453-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for benign meningioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign meningioma developing late lung metastases: case report and review of the literature.
  • Here we report the case of a 65-year-old female with a histologically benign parietal falcine meningioma who developed multiple lung metastases 15 years after tumor resection.
  • Since it was diagnosed as a benign meningothelial meningioma Grade I WHO, the residual tumor was followed with serial imaging without adjuvant treatment.
  • The patient subsequently developed lung lesions later identified as metastases.
  • The lung lesions were successfully removed surgically and histologically diagnosed as meningothelial meningioma Grade I WHO.
  • A repeat brain MRI revealed the known residual meningioma with no signs of interval tumor growth, but did demonstrate occlusion of the sagittal sinus.
  • A review of the literature revealed only 15 well-documented cases of benign meningiomas that metastasized in an interval of up to 12 years after primary tumor resection.
  • This case illustrates that histologically benign meningiomas Grade I WHO with stable disease of the primary tumor have the potential to develop hematogenous metastases even after a long time interval.
  • [MeSH-major] Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary
  • [MeSH-minor] Aged. Female. Humans. Neoplasm, Residual. Time Factors

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919820.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 25
  •  go-up   go-down


32. Idrees MT, Huan Y, Woo P, Wang BY: Inflammatory myofibroblastic tumor of larynx: a benign lesion with variable morphological spectrum. Ann Diagn Pathol; 2007 Dec;11(6):433-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of larynx: a benign lesion with variable morphological spectrum.
  • Inflammatory myofibroblastic tumor is a recently characterized lesion, composed of exuberant myofibroblastic proliferation and an inflammatory component.
  • Its etiology remains controversial, as to whether this represents a benign tumor with limited potential to recur or progress.
  • Only a few cases of laryngeal inflammatory myofibroblastic tumor have been described in English after it has been assigned the new name.
  • The prototype lesion, inflammatory pseudotumor, has been best described in association with the lung but has also been reported involving various organs.
  • This uncommon neoplasm may appear clinically as a large infiltrating mass and may be mistaken as a malignant growth.
  • Conservative resection of the tumor may provide a cure with adequate voice preservation.

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18022129.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Nucci MR, Drapkin R, Dal Cin P, Fletcher CD, Fletcher JA: Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications. Am J Surg Pathol; 2007 May;31(5):737-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications.
  • "Benign metastasizing leiomyoma" is the terminology used to describe a controversial entity characterized by a proliferation of bland-appearing smooth muscle in lung or abdominopelvic lymph nodes.
  • In this report, we describe 5 cases of pulmonary-based smooth muscle tumors that are clinically and histologically consistent with this entity, and in which we identified consistent chromosomal aberrations (19q and 22q terminal deletion in all cases).
  • This cytogenetic profile is found in approximately 3% of uterine leiomyoma, but has not been described in other types of benign or malignant neoplasia.
  • These findings suggest that the nodular pulmonary smooth muscle proliferations termed "benign metastasizing leiomyoma," are a genetically distinct entity, which likely originate from a biologically distinctive subset of uterine leiomyoma.
  • [MeSH-major] Chromosome Aberrations. Leiomyoma / pathology. Lung Neoplasms / secondary. Uterine Neoplasms / pathology
  • [MeSH-minor] Actins / analysis. Biomarkers, Tumor. Chromosome Deletion. Chromosomes, Human, Pair 19. Chromosomes, Human, Pair 22. Desmin / analysis. Female. Humans. Karyotyping. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460458.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Desmin
  •  go-up   go-down


34. Song SW, Jung JI, Lee KY, Kim MY, Park SH: Malignant solitary fibrous tumor of the pleura: computed tomography-pathological correlation and comparison with computed tomography of benign solitary fibrous tumor of the pleura. Jpn J Radiol; 2010 Oct;28(8):602-8
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant solitary fibrous tumor of the pleura: computed tomography-pathological correlation and comparison with computed tomography of benign solitary fibrous tumor of the pleura.
  • PURPOSE: The aim of this study was to determine the computed tomography (CT)-pathological correlation of malignant solitary fibrous tumors of the pleura (MSFP) and to compare these findings with CT findings of benign solitary fibrous tumors of the pleura (BSFTP).
  • Pleural metastasis (57.1%) and lung metastasis (14.3%) were associated.
  • [MeSH-major] Solitary Fibrous Tumor, Pleural / radiography. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20972860.001).
  • [ISSN] 1867-108X
  • [Journal-full-title] Japanese journal of radiology
  • [ISO-abbreviation] Jpn J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


35. Fang FC, Lee SC, Hsu HH, Peng YJ, Chang H, Cheng YL: Inflammatory myofibroblastic tumor of the lung: unusual presentation. Lung; 2008 May-Jun;186(3):191-193
Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the lung: unusual presentation.
  • Inflammatory myofibroblastic tumor (IMT) of the lung is a rare entity considered to be a benign neoplastic lesion.
  • Because of its variable cellular composition, it seldom allows diagnosis preoperatively either through transthoracic fine-needle aspiration or bronchoscopic biopsy.
  • In this report we describe a unique occurrence of a rarely described large inflammatory myofibroblastic tumor of the lung that mimics a posterior mediastinal tumor in a 45-year-old female, detailing clinical presentation, imaging, and management.
  • [MeSH-major] Plasma Cell Granuloma, Pulmonary / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Middle Aged. Pneumonectomy. Radiography, Thoracic. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297338.001).
  • [ISSN] 0341-2040
  • [Journal-full-title] Lung
  • [ISO-abbreviation] Lung
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Asioli S, Senetta R, Maldi E, D'Ambrosio E, Satolli MA, Bussolati G, Cassoni P: "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung. Virchows Arch; 2007 May;450(5):591-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung.
  • Lung "metastases" of benign meningiomas are rarely described events of biological and clinical interest.
  • We, here, report of a 70-year-old healthy woman found by CT scan to have multiple lesions, the two largest in the right lung on routine examination.
  • The larger lung lesion was a 3-cm node located in the right lung and was removed by wedge resection.
  • The morphological and immunohistochemical features of this lesion, together with the similarity with the original cerebral tumour and its indolent evolution, led to a final diagnosis of "benign" meningioma metastatic to the lung.
  • Lung metastatic meningiomas may be a diagnostic challenge because of their unusual site of presentation and the possible confusion with primitive lung meningiomas or primary mesenchymal lung lesions.
  • They represent a typical example of "benign" tumours that may implant to the lung similar to other tumours, definitely considered benign but reported to rarely present unusual secondary localization.
  • [MeSH-major] Brain Neoplasms / pathology. Lung Neoplasms / secondary. Meningioma / secondary
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Neoplasm Metastasis / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431673.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Saad RS, Liu YL, Silverman JF: Distribution of basal/myoepithelial markers in benign and malignant bronchioloalveolar proliferations of the lung. Appl Immunohistochem Mol Morphol; 2010 May;18(3):219-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of basal/myoepithelial markers in benign and malignant bronchioloalveolar proliferations of the lung.
  • We investigated the staining pattern of commonly used basal cell/myoepithelial markers, such as p63 (a p53-homologous nuclear protein), basal cell-specific cytokeratin antibody (34betaE12, K903), and smooth muscle myosin heavy chain (SMMHC) in benign and malignant bronchioloalveolar proliferations of the lung.
  • We studied 85 lung lesions consisting of 35 bronchioloalveolar carcinoma, 30 well-differentiated adenocarcinoma, and 20 cases of benign lung lesions.
  • In normal lung, p63, K903, and SMMHC decorated the basal cells of large and small airways and occasional cells of terminal bronchioles.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065853.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 3.6.1.- / Smooth Muscle Myosins
  •  go-up   go-down


38. Neuman J, Rosioreanu A, Schuss A, Turi G, Yung E, Trow TK, Williams L, Katz DS: Radiology-pathology conference: sclerosing hemangioma of the lung. Clin Imaging; 2006 Nov-Dec;30(6):409-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiology-pathology conference: sclerosing hemangioma of the lung.
  • Sclerosing hemangioma (SH) is a relatively rare, benign neoplasm of the lung.
  • We report the radiology and pathology of a patient with a SH, with emphasis on the computed tomographic and (18)F-fluorodeoxyglucose positron emission tomography findings, and review the literature on this unusual tumor.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung / radiography. Lung / radionuclide imaging. Positron-Emission Tomography / methods. Pulmonary Sclerosing Hemangioma / diagnosis. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101410.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 18
  •  go-up   go-down


39. Vijayabhaskar R, Mehta SS, Deodhar KK, Pramesh CS, Mistry RC: PEComa of the lung. J Cancer Res Ther; 2010 Jan-Mar;6(1):109-11
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PEComa of the lung.
  • Perivascular epithelioid cell tumor (PEComa), also called clear cell ''sugar'' tumor of the lung, is a rare benign tumor arising from perivascular epithelioid cells (PECs).
  • We report a case of a 15-year-old boy who presented with right lower lobe lesion which turned out to be a clear cell tumor of the lung.
  • An [18F]-fluoro-2-deoxy-D-glucose (FDG) - positron emission tomography (PET) scan revealed mild FDG uptake in the lung lesion (SUV< 1) with no active uptake elsewhere in the body.
  • We discuss the clinical, radiologic and immunohistochemical features of clear cell ''sugar'' tumor of lung and compare them with published literature.
  • [MeSH-major] Lung Neoplasms / pathology. Perivascular Epithelioid Cell Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479562.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


40. D'Armiento J, Imai K, Schiltz J, Kolesnekova N, Sternberg D, Benson K, Pardo A, Selman M, Smolarek T, Vundavalli M, Sonnet J, Szabolcs M, Chada K: Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis. Cancer Res; 2007 Mar 1;67(5):1902-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis.
  • A detailed in situ hybridization analysis showed that the undifferentiated mesoderm of the embryonic lung expressed Hmga2 but it was not expressed in the newborn or adult lung.
  • Previously, HMGA2 was shown to be misexpressed in a number of benign, differentiated mesenchymal tumors including lipomas, uterine leiomyomas, and pulmonary chondroid hamartomas.
  • Here, we show that HMGA2 is misexpressed in pulmonary lymphangiomyomatosis (LAM), a severe disorder of unknown etiology consisting of lymphatic smooth muscle cell proliferation that results in the obstruction of airways, lymphatics, and vessels.
  • Immunohistochemistry was done with antibodies to HMGA2 and revealed expression in lung tissue samples obtained from 21 patients with LAM.
  • In contrast, HMGA2 was not expressed in sections of normal adult lung or other proliferative interstitial lung diseases, indicating that the expression of HMGA2 in LAM represents aberrant gene activation and is not due solely to an increase in cellular proliferation.
  • In vivo studies in transgenic mice show that misexpression of HMGA2 in smooth muscle cells resulted in increased proliferation of these cells in the lung surrounding the epithelial cells.
  • [MeSH-major] HMGA2 Protein / metabolism. Lung Neoplasms / metabolism. Lymphangioleiomyomatosis / metabolism
  • [MeSH-minor] Animals. Female. Humans. In Situ Hybridization, Fluorescence. Lung / embryology. Lung / metabolism. Mice. Mice, Inbred C57BL. Mice, Inbred CBA. Mice, Transgenic. Myocytes, Smooth Muscle / metabolism


41. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M: A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev; 2007 Feb 15;21(4):379-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.
  • BRaf(CA) mice infected with an Adenovirus expressing Cre recombinase developed benign lung tumors that only rarely progressed to adenocarcinoma.
  • Moreover, BRaf(VE)-induced lung tumors were prevented by pharmacological inhibition of MEK1/2.
  • Consistent with Ink4a/Arf and TP53 tumor suppressor function, BRaf(VE) expression combined with mutation of either locus led to cancer progression.


42. Mizobuchi T, Masahiro N, Iwai N, Kohno H, Okada N, Nakada S: Clear cell tumor of the lung: surgical and immunohistochemical findings. Gen Thorac Cardiovasc Surg; 2010 May;58(5):243-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell tumor of the lung: surgical and immunohistochemical findings.
  • We encountered a clear cell tumor of the lung (CCTL) that was located peripherally, adjacent to the visceral pleura.
  • The tumor could be directly observed during surgery.
  • A chest radiograph during routine examination of an asymptomatic 65-year-old woman being treated for hypertension and hyperlipidemia revealed a nodular shadow in the left lung field.
  • The in vivo color of the tumor was red, suddenly changing to white after the tumor was clamped.
  • Immunohistochemistry revealed tumor cells positive for vimentin and melanocytic markers (HMB-45 and melan-A) and negative for epithelial membrane antigen and cytokeratin.
  • With the absence of clinical findings in both kidneys, the tumor was diagnosed as a benign CCTL.
  • [MeSH-major] Biomarkers, Tumor / analysis. Immunohistochemistry. Lung Neoplasms / chemistry. Lung Neoplasms / surgery. Perivascular Epithelioid Cell Neoplasms / chemistry. Perivascular Epithelioid Cell Neoplasms / surgery. Thoracic Surgery, Video-Assisted
  • [MeSH-minor] Aged. Antigens, Neoplasm / analysis. Female. Humans. Incidental Findings. MART-1 Antigen. Melanoma-Specific Antigens. Neoplasm Proteins / analysis. Tomography, X-Ray Computed. Treatment Outcome. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20449716.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / Vimentin
  •  go-up   go-down


43. Molina R, Augé JM, Bosch X, Escudero JM, Viñolas N, Marrades R, Ramírez J, Carcereny E, Filella X: Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol; 2009;30(3):121-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
  • BACKGROUND: Tumor markers have been extensively studied in lung cancer, reporting some relationship to the histology, but their clinical utility is not clear.
  • METHODS: ProGRP, CEA, SCC, CA 125, CYFRA 21-1 and NSE were studied prospectively in 155 patients with unconfirmed suspicion of lung cancer and in 647 patients with lung cancer: 182 squamous, 205 adenocarcinomas, 19 large-cell lung cancer (LCLC), 175 small-cell lung cancer (SCLC) and 66 unspecific non-small-cell lung cancer (NSCLC).
  • RESULTS: Abnormal tumor marker serum levels were found in less than 5.3% of the patients with benign diseases, excluding CA 125 (21.3%).
  • Tumor markers were related to histological type and tumor extension with significantly higher CEA (p <0.01) and CA 125 (p <0.007) serum levels in adenocarcinomas, SCC (p <0.0001) and CYFRA 21-1 (p <0.008) in squamous tumors and ProGRP (p <0.0001) and NSE (p <0.0001) in SCLC.
  • Tumor markers may be useful in the histological differentiation of NSCLC and SCLC.
  • CONCLUSIONS: Tumor marker determination in patients with suspicious signs of lung cancer suggests, in a few hours, the histological diagnosis in the majority of lung cancer patients.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Squamous Cell / blood. Lung Neoplasms / blood. Peptide Fragments / blood. Small Cell Lung Carcinoma / blood
  • [MeSH-minor] Algorithms. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins / blood. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19506400.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptide Fragments; 0 / Recombinant Proteins; 0 / pro-gastrin-releasing peptide (31-98)
  •  go-up   go-down


44. Liu J, Zheng S, Yu JK, Zhang JM, Chen Z: Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. J Zhejiang Univ Sci B; 2005 Jan;6(1):4-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor.
  • To screen and evaluate protein biomarkers for the detection of gliomas (Astrocytoma grade I-IV) from healthy individuals and gliomas from brain benign tumors by using surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) coupled with an artificial neural network (ANN) algorithm.
  • SELDI-TOF-MS protein fingerprinting of serum from 105 brain tumor patients and healthy individuals, included 28 patients with glioma (Astrocytoma I-IV), 37 patients with brain benign tumor, and 40 age-matched healthy individuals.
  • An accuracy of 95.7%, sensitivity of 88.9%, specificity of 100%, positive predictive value of 90% and negative predictive value of 100% were obtained in a blinded test set comparing gliomas patients with healthy individuals; an accuracy of 86.4%, sensitivity of 88.9%, specificity of 84.6%, positive predictive value of 90% and negative predictive value of 85.7% were obtained when patient's gliomas was compared with benign brain tumor.
  • The high sensitivity and specificity achieved by the use of selected biomarkers showed great potential application for the discrimination of gliomas patients from healthy individuals and gliomas from brain benign tumors.
  • [MeSH-major] Astrocytoma / blood. Astrocytoma / diagnosis. Biomarkers, Tumor / blood. Brain Neoplasms / blood. Brain Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Neoplasm Proteins / blood. Peptide Mapping / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Pain. 2003 Apr;102(3):251-6 [12670666.001]
  • [Cites] Curr Med Chem. 2003 May;10(10):831-43 [12678686.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):267-79 [12781425.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Feb;5(1):45-67 [14965209.001]
  • [Cites] Curr Opin Biotechnol. 2004 Feb;15(1):24-30 [15102462.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Bioinformatics. 2002 Mar;18(3):395-404 [11934738.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2541-52 [12171882.001]
  • (PMID = 15593384.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Letter; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1390751
  •  go-up   go-down


45. Ma XC, Zhang ZT, Ou SL, Hu YS, Song FQ, Zhang SY: [Experience in lung resection synchronous with off-pump coronary artery bypass grafting in patients with lung tumor and coronary disease]. Zhonghua Yi Xue Za Zhi; 2007 Jul 3;87(25):1758-60
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experience in lung resection synchronous with off-pump coronary artery bypass grafting in patients with lung tumor and coronary disease].
  • OBJECTIVE: To summarize the experience in lung resection synchronous with off-pump coronary artery bypass grafting (OPCABG) in patients with lung tumor and coronary disease.
  • METHODS: The clinical data of ten patients with coronary artery disease and lung tumor, 8 with peripheral malignant tumors and 2 with central benign tumors, all males, aged 56.2 (41 - 782), who underwent lung resection and OPCABG synchronously, were analyzed.
  • CONCLUSION: With experienced management, it is feasible and safe to perform lung resection and OPCABG synchronously for strictly selected patients.
  • [MeSH-major] Coronary Artery Bypass. Coronary Disease / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Aged. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919382.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


46. Zhao ZL, Huang QY, Xu S, Zhang L, Zhao HR: [Expression of promyelocytic leukaemia protein in lung carcinomas and clinical significance thereof]. Zhonghua Yi Xue Za Zhi; 2006 Dec 19;86(47):3362-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of promyelocytic leukaemia protein in lung carcinomas and clinical significance thereof].
  • OBJECTIVE: To investigate the expression of promyelocytic leukaemia (PML) protein in lung carcinomas and the clinical significance thereof.
  • METHODS: A tumor tissue microarray with lung samples from 148 patients with lung carcinoma and 5 patients with pulmonary benign tumor, and 7 patients with other benign diseases resected during operation.
  • The cases with at least triplicate 0.6-mm cores per tumor or tissue were analyzed.
  • RESULTS: Four cases of lung carcinoma were excluded because their available cores were less than 3.
  • The remaining 144 lung carcinoma cases included 45 cases with squamous cell carcinoma, 62 with adenocarcinoma, 23 with small cell lung carcinoma (SCLC), 7 with large cell carcinoma, 5 with pleomorphic carcinoma, 1 with carcinoid, and 1 with adenosquamous carcinoma.
  • Among the 5 cases with benign lung tumors, two cases with pulmonary leiomyomas had strong expression of PML.
  • The rates of PML expression on cell nuclei were 31.4% and 8.7% respectively in the non-small cell lung carcinoma (NSCLC) and SCLC samples (chi(2) = 4.968, P = 0.026).
  • CONCLUSION: As an important suppressor of tumor, PML may be a useful indicator to predict postoperative prognosis in patients with SCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Small Cell / metabolism. Lung Neoplasms / metabolism. Neoplasm Proteins / biosynthesis. Nuclear Proteins / biosynthesis. Transcription Factors / biosynthesis. Tumor Suppressor Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313836.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 143220-95-5 / PML protein, human
  •  go-up   go-down


47. Ohtsuka T, Nomori H, Watanabe K, Naruke T: [Benign metastasizing leiomyoma of the lung. Report of a case]. Nihon Kokyuki Gakkai Zasshi; 2005 Feb;43(2):99-102
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign metastasizing leiomyoma of the lung. Report of a case].
  • Benign metastasizing leiomyoma (BML) is the term used to describe multiple benign pulmonary leiomyomatous lesions occurring in patients with a previous history of uterine leiomyoma.
  • A chest X-ray showed multiple nodules in bilateral lung.
  • Chest computed tomography (CT) scan showed round nodules well-defined margins in bilateral lung.
  • Thoracoscopic partial resection of the lung was performed.
  • Pathological examination revealed that the tumor composed of spindle-shaped smooth muscle cells and its characteristics were remarkably similar to those of the previously resected uterine leiomyoma.
  • Therefore, these lung tumors could be considered to be lung metastases from a uterine leiomyoma (benign metastasizing leiomyoma).
  • [MeSH-major] Leiomyoma / pathology. Lung Neoplasms / secondary. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770941.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


48. Onuma K, Sato Y, Ogawara S, Shirasawa N, Kobayashi M, Yoshitake J, Yoshimura T, Iigo M, Fujii J, Okada F: Nano-scaled particles of titanium dioxide convert benign mouse fibrosarcoma cells into aggressive tumor cells. Am J Pathol; 2009 Nov;175(5):2171-83
Hazardous Substances Data Bank. TITANIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nano-scaled particles of titanium dioxide convert benign mouse fibrosarcoma cells into aggressive tumor cells.
  • We found that mice that were cotransplanted subcutaneously with QR-32 cells and nano-sized TiO(2), either uncoated (TiO(2)-1, hydrophilic) or coated with stearic acid (TiO(2)-2, hydrophobic), did not form tumors.
  • However, QR-32 cells became tumorigenic after injection into sites previously implanted with TiO(2)-1, but not TiO(2)-2, and these developing tumors acquired metastatic phenotypes.
  • These results indicate that nano-sized TiO(2) has the potential to convert benign tumor cells into malignant ones through the generation of ROS in the target cells.
  • [MeSH-major] Cell Transformation, Neoplastic / drug effects. Fibrosarcoma. Nanoparticles / chemistry. Neoplasm Invasiveness. Titanium / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cytokines / genetics. Cytokines / metabolism. Deoxyguanosine / analogs & derivatives. Deoxyguanosine / metabolism. Dinoprostone / metabolism. Female. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Mice. Mice, Inbred C57BL. Particle Size. Reactive Oxygen Species / metabolism. Thymosin / genetics. Thymosin / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • Hazardous Substances Data Bank. TITANIUM DIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Occup Med. 1988 Dec;30(12):937-42 [3230444.001]
  • [Cites] J Toxicol Environ Health. 1990;29(4):417-29 [2325155.001]
  • [Cites] Cancer Immunol Immunother. 1990;31(6):358-64 [2386981.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):635-9 [1419599.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):233-8 [8054271.001]
  • [Cites] J Immunol. 1996 Dec 15;157(12):5512-20 [8955201.001]
  • [Cites] J Biochem. 1997 Aug;122(2):459-66 [9378727.001]
  • [Cites] Br Med Bull. 1997;53(3):662-8 [9374044.001]
  • [Cites] FEBS Lett. 1997 Nov 24;418(1-2):87-90 [9414101.001]
  • [Cites] Exp Lung Res. 1998 Jan-Feb;24(1):85-100 [9457471.001]
  • [Cites] Am J Physiol. 1998 Jan;274(1 Pt 1):L81-6 [9458804.001]
  • [Cites] J Appl Toxicol. 1998 Sep-Oct;18(5):307-12 [9804429.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):377-85 [10027302.001]
  • [Cites] Skin Pharmacol Appl Skin Physiol. 1999 Sep-Oct;12(5):247-56 [10461093.001]
  • [Cites] FASEB J. 2005 Mar;19(3):311-30 [15746175.001]
  • [Cites] Exp Cell Res. 2005 Apr 15;305(1):51-62 [15777787.001]
  • [Cites] J Am Chem Soc. 2005 Mar 30;127(12):4388-96 [15783221.001]
  • [Cites] Environ Health Perspect. 2005 Jul;113(7):823-39 [16002369.001]
  • [Cites] Toxicology. 2005 Sep 15;213(1-2):66-73 [15970370.001]
  • [Cites] Environ Health Perspect. 2005 Nov;113(11):1555-60 [16263511.001]
  • [Cites] Nitric Oxide. 2006 Mar;14(2):122-9 [16125421.001]
  • [Cites] Environ Health Perspect. 2006 Mar;114(3):341-9 [16507455.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):854-62 [16508635.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):295-6 [16598890.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):294-302 [16816381.001]
  • [Cites] FASEB J. 2006 Nov;20(13):2393-5 [17023518.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):18882-6 [17135351.001]
  • [Cites] Toxicol Lett. 2007 Jan 10;168(1):58-74 [17141434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2029-30 [17284585.001]
  • [Cites] Water Sci Technol. 2006;54(11-12):327-34 [17302336.001]
  • [Cites] Mutat Res. 2007 Apr 2;628(2):99-106 [17223607.001]
  • [Cites] Biomaterials. 2007 Jul;28(19):2946-58 [17379299.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2364-72 [17893867.001]
  • [Cites] Oncogene. 2008 Nov 27;27(56):7070-82 [18806824.001]
  • [Cites] Tumour Biol. 2000 Jan-Feb;21(1):11-20 [10601837.001]
  • [Cites] Toxicology. 2001 Aug 28;165(2-3):133-44 [11522371.001]
  • [Cites] Photochem Photobiol. 2001 Nov;74(5):656-69 [11723793.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):869-82 [11891186.001]
  • [Cites] Proc Nutr Soc. 2002 Feb;61(1):123-30 [12002786.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 7):5-11 [12068382.001]
  • [Cites] Biomaterials. 2002 Sep;23(17):3757-64 [12109701.001]
  • [Cites] Toxicol In Vitro. 2002 Oct;16(5):629-35 [12206830.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):455-60 [12676598.001]
  • [Cites] J Biosci. 2003 Feb;28(1):51-5 [12682424.001]
  • [Cites] Pharmacol Ther. 2003 Jul;99(1):113-32 [12804702.001]
  • [Cites] Prog Lipid Res. 2003 Nov;42(6):463-78 [14559067.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2221-32 [14633597.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Feb;286(2):L344-53 [14555462.001]
  • [Cites] Water Sci Technol. 2004;49(1):103-10 [14979544.001]
  • [Cites] Free Radic Biol Med. 2004 Oct 1;37(7):916-25 [15336307.001]
  • [Cites] J Nanosci Nanotechnol. 2004 May;4(5):521-31 [15503438.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 May;72(5):1848-51 [1057174.001]
  • [Cites] Ann N Y Acad Sci. 1976;276:455-65 [1071971.001]
  • [Cites] Int J Cancer. 1987 Mar 15;39(3):338-42 [2434441.001]
  • [Cites] Scand J Work Environ Health. 1987 Feb;13(1):47-51 [3495034.001]
  • (PMID = 19815711.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Intercellular Signaling Peptides and Proteins; 0 / Reactive Oxygen Species; 0 / Vascular Endothelial Growth Factor A; 15FIX9V2JP / titanium dioxide; 61512-21-8 / Thymosin; 77591-33-4 / thymosin beta(4); 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; D1JT611TNE / Titanium; G9481N71RO / Deoxyguanosine; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC2774079
  •  go-up   go-down


49. Hoetzenecker K, Ankersmit HJ, Aigner C, Lichtenauer M, Kreuzer S, Hacker S, Hoetzenecker W, Lang G, Klepetko W: Consequences of a wait-and-see strategy for benign metastasizing leiomyomatosis of the lung. Ann Thorac Surg; 2009 Feb;87(2):613-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consequences of a wait-and-see strategy for benign metastasizing leiomyomatosis of the lung.
  • Pulmonary benign metastasizing leiomyomatosis (BML) is a rare smooth-muscle cell disorder of the lung.
  • Herein, we present a case of BML in which a wait-and-see strategy after diagnosis was decided.
  • Fourteen years later a routine chest roentgenogram revealed multiple bi-lobar BML lesions with a giant cyst filling the whole left lung cavity.
  • We conclude that a wait-and-see procedure for BML is feasible, but primary resection of the BML tumor masses is preferable to avoid complications as described in our case.
  • [MeSH-major] Leiomyomatosis / pathology. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Observation / methods. Pneumonectomy / methods. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19161793.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


50. Bodner-Adler B, Bartl M, Wagner G: Intravenous leiomyomatosis of the uterus with pulmonary metastases or a case with benign metastasizing leiomyoma? Anticancer Res; 2009 Feb;29(2):495-6
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravenous leiomyomatosis of the uterus with pulmonary metastases or a case with benign metastasizing leiomyoma?
  • BACKGROUND: Intravenous leiomyomatosis (IVL) is defined as an intraluminal growth of benign smooth muscle cells in either venous or lymphatic vessels outside the confines or even in the absence of leiomyomas.
  • Benign metastasizing uterine leiomyoma is defined as a histologically benign uterine smooth muscle tumor that acts in a somewhat malignant fashion and produces benign metastases.
  • Postoperatively, the patient developed a pulmonary embolism and additionally diffuse, multiple nodules of the lungs were detected in the lung scan.
  • An open lung biopsy led to the diagnosis of pulmonary leiomyomatosis.
  • The patient was put on a regimen of gonadotropin-releasing hormone for a total of 6 months and a lung scan after 6 months revealed stable disease.
  • CONCLUSION: Though intravenous leiomyomatosis imitates a malignant neoplasm concerning the pattern of growth and extension, and benign metastasizing leiomyoma produces benign metastases, they must be differentiated histologically from malignant tumors to prevent overtreatment.
  • [MeSH-major] Leiomyoma / pathology. Leiomyomatosis / pathology. Lung Neoplasms / secondary. Uterine Neoplasms / pathology. Vascular Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans


51. Egberts JH, Schafmayer C, Bauerschlag DO, Jänig U, Tepel J: Benign abdominal and pulmonary metastasizing leiomyoma of the uterus. Arch Gynecol Obstet; 2006 Aug;274(5):319-22
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign abdominal and pulmonary metastasizing leiomyoma of the uterus.
  • BACKGROUND: Benign metastasizing leiomyoma (BML) is a rare disease in which the lung is described to be the most afflicted extrauterine organ.
  • METHODS: We report of a 42-year-old African woman with a BML in the abdomen and lung who had undergone a hysterectomy for uterine leiomyoma 10 years ago.
  • She was admitted to our hospital for investigation of a huge tumor mass in the pelvis consisting of multiple nodules in the abdomen and left lung.
  • Assuming an advanced intraperitoneal malignancy was present, a 'palliative' limited tumor debulking and due to a tumor compressing the sigmoid a Hartmann's procedure was performed.
  • CONCLUSIONS: The review of the literature supports the concept that the primary tumor of BML is located in the uterus and that leiomyomas in the uterus can metastasize leading via hematogenous spread to BML.
  • However, the origin of the tumor remains controversial.
  • [MeSH-major] Abdomen. Leiomyoma / pathology. Lung Neoplasms / secondary. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16649038.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


52. Nie GJ, Feng FF, Wu YJ, Wu YM: [Diagnosis and prediction of lung cancer through different classification techniques with tumor markers]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2009 May;27(5):257-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and prediction of lung cancer through different classification techniques with tumor markers].
  • OBJECTIVE: To study which classification model was most suitable for establishing a multi-tumor markers lung cancer prediction model, through established logistic regression model, decision trees model and artificial neural network model.
  • METHODS: RIA analysis, ELISA, spectrophotometry, high-performance liquid chromatography (HPLC) and atomic absorption spectrometry were used to measure the serum CEA, CA125, gastrin, NSE, beta2-MG, Sil-6 receptors, sialic acid, nitric oxide, Cu, Zn, Ca and the pseudo-urine nucleoside of urine samples in lung cancer patients, benign lung disease patients and healthy controls.
  • The lung cancer diagnosis models were established by logistic regression analysis, decision tree analysis and artificial neural network training.
  • RESULTS: The diagnosis sensitivities of the logistic regression analysis, decision tree analysis and artificial neural network model with 12 tumor markers in lung cancer were 94.00%, 100.00% and 100.00%; the specificity were 100.00%, 98.89% and 100.00%; the total accurate 94.29%, 95.00% and 90.00%, respectively.
  • CONCLUSION: The results of three classification models with 12 tumor markers in diagnosis of lung cancer are ideal.
  • Especially the C5.0 decision tree model and the artificial neural network model are more suitable for the prediction and diagnosis of the lung cancer.
  • [MeSH-major] Decision Trees. Logistic Models. Lung Neoplasms / diagnosis. Neural Networks (Computer)
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538834.001).
  • [ISSN] 1001-9391
  • [Journal-full-title] Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
  • [ISO-abbreviation] Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


53. Zhao Z, Huang Q, Zhao T, Zhao J: [Expression and clinical significance of PML, P53 and P16INK4A in lung cancer]. Zhongguo Fei Ai Za Zhi; 2007 Jun 20;10(3):176-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of PML, P53 and P16INK4A in lung cancer].
  • BACKGROUND: The promyelocytic leukaemia (PML) protein has been implicated in control of key tumor-suppressive pathways.
  • However, its role in pathogenesis of lung cancer is still unclear.
  • The objective of this study is to assess expression and clinical significance of PML, P53 and P16INK4A in lung cancer, as well as the relation of these factors.
  • METHODS: The tissue microarrays were created with samples from lung cancers (n=148), pulmonary benign lung tumors (n=5) and normal lung tissues (n=7), and protein expression was analyzed by immunohistochemical staining.
  • RESULTS: There was at least triplicate 0.6-mm cores per sample, 4 cases of lung cancer were excluded for lacking of enough tissue.
  • P53 expression was found in 33.3% lung cancer, and absent in benign tumors and normal tissues of the lung (P=0.038).
  • P16INK4A expression was abolished in normal lung tissue, however, increased in lung cancer (28.5%), and especially in lung cancer with non- or poor differentiation (36.5%) and in SCLC (69.6%).
  • There was inverse correlation between PML expression in the nuclei and P16INK4A expression, positive correlation between P53 and P16INK4A expressions in lung cancers.
  • CONCLUSIONS: As an important suppressor of tumor, PML is related with P53 mutation in squamous cell carcinoma.
  • Increased P16INK4A protein in lung cancer may be the results of gene mutation, and be related with mutant P53 protein.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21118641.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


54. Jin MS, Ha HJ, Baek HJ, Lee JC, Koh JS: Adenomyomatous hamartoma of lung mimicking benign mucinous tumor in fine needle aspiration biopsy: a case report. Acta Cytol; 2008 May-Jun;52(3):357-60
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomyomatous hamartoma of lung mimicking benign mucinous tumor in fine needle aspiration biopsy: a case report.
  • Cytologic features of adenomyomatous hamartoma, a special variant of PH, are not documented in the literature and are confused with epithelial neoplasm in the case of sparse stromal cellularity.
  • Fine needle aspiration biopsy (FNAB) revealed numerous mucinous epithelial cells presenting predominantly in cohesive cellular sheets that suggested benign mucinous epithelial lesion.
  • The patient underwent surgery for the tumor, and it was histologically proven to be an adenomyomatous hamartoma.
  • This case demonstrates the wide spectrum of PH in FNAB and led us to consider PH as a differential diagnosis despite lack of chondromyxoid stromal components.
  • [MeSH-major] Biopsy, Fine-Needle. Hamartoma / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / pathology. Diagnosis, Differential. Humans. Male. Middle Aged. Thoracic Surgery, Video-Assisted. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540306.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Molina R, Auge JM, Filella X, Viñolas N, Alicarte J, Domingo JM, Ballesta AM: Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer Res; 2005 May-Jun;25(3A):1773-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
  • We studied the specificity and sensitivity of progastrin releasing peptide (ProGRP) in 37 healthy subjects and 195 patients with benign and 149 with malignant diseases other than lung cancer.
  • Likewise, we compared the ProGRP with other tumor markers used in lung cancer (CEA, SCC, CYFRA and NSE) in 187 patients with NSCLC and in 66 SCLC patients.
  • Abnormal ProGRP serum levels were found in 10% of patients with benign diseases and in 13% of patients with malignancies other than lung.
  • Slightly raised ProGRP serum levels, excluding renal failure, were found in 4.1% of patients with benign diseases (<80 pg/ml) and in 5% of patients with malignancies other than lung cancer or neuroendocrine tumors (<120 pg/ml).
  • Tumor marker serum levels were related to histological type and tumor extension, with ProGRP being the most sensitive marker in SCLC, CEA in adenocarcinomas and CYFRA 21-1 in squamous tumors.
  • The most sensitive combinations of tumor markers were ProGRP and NSE in SCLC (88%), and CEA plus CYFRA in NSCLC (82%).
  • In summary, ProGRP is the tumor marker of choice in SCLC and NSE is a complementary tumor marker in this histological type.
  • [MeSH-major] Antigens, Neoplasm / blood. Carcinoembryonic Antigen / blood. Gastrointestinal Hormones / blood. Lung Neoplasms / blood. Phosphopyruvate Hydratase / blood. Serpins / blood
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Case-Control Studies. Humans. Keratin-19. Keratins. Middle Aged. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033098.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Gastrointestinal Hormones; 0 / Keratin-19; 0 / Serpins; 0 / antigen CYFRA21.1; 0 / squamous cell carcinoma-related antigen; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


56. Safranek J, Pesta M, Holubec L, Kulda V, Dreslerova J, Vrzalova J, Topolcan O, Pesek M, Finek J, Treska V: Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res; 2009 Jul;29(7):2513-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease.
  • The expression of matrix metallo-proteinases (MMP-7 and MMP-9) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2), which are involved in the degradation of the extracellular matrix (ECM) and tumor growth, was investigated in normal lung tissue, tissue of benign pulmonary diseases and non-small cell lung cancer (NSCLC) tissue.
  • PATIENTS AND METHODS: Tumor tissue and surrounding carcinoma-free lung tissue samples were obtained from 91 patients with NSCLC who had undergone surgery in the years 2005-2007 as well as lung tissue from 12 patients operated on for 'benign' bullous emphysema or interstitial lung disease.
  • RESULTS: Significantly higher expression of MMP-7, MMP-9 and TIMP-1 mRNA was demonstrated in the NSCLC tissue in comparison with the normal lung tissue from the same patients (p=0.0003, p<0.0001 and p=0.0018, respectively).
  • Similar results for MMP-7, MMP-9 and TIMP-1 were found in the histological subgroups: squamous cell lung cancer vs. normal tissue (p=0.0198, p=0.0015 and p=0.0366, respectively), and adenocarcinoma vs. normal tissue (p=0.0045, p<0.0001 and p=0.0140, respectively).
  • The expression of MMP-7 was found to be significantly higher in tumor tissue vs. lung tissue of the benign diseases (p=0.0086) and similar results were also recorded in the histological subgroups: squamous cell lung cancer vs. benign tissue (p=0.0171) and adenocarcinoma vs. benign tissue (p=0.0135).
  • The expression of MMP-9 was significantly higher only in the adenocarcinoma subgroup vs. the benign tissue (p=0.0412).
  • CONCLUSION: Significantly higher expression of MMP-7 and MMP-9 in tumor tissue than in the surrounding tissue or in benign lung disease tissue supports the notion of an important role of these metalloproteinases in the growth of lung carcinoma.
  • TIMP-1 expression is increased only in carcinoma, but not in benign lung disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Diseases / metabolism. Lung Neoplasms / metabolism. Matrix Metalloproteinase 7 / genetics. Matrix Metalloproteinase 9 / genetics. Tissue Inhibitor of Metalloproteinase-1 / genetics. Tissue Inhibitor of Metalloproteinase-2 / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Pulmonary Disease.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596921.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


57. Kourda J, Ismail O, Smati BH, Ayadi A, Kilani T, El Mezni F: Benign myoepithelioma of the lung - a case report and review of the literature. Cases J; 2010;3(1):25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign myoepithelioma of the lung - a case report and review of the literature.
  • INTRODUCTION: Benign myoepithelioma is extremely rare in the lung, to the best of our knowledge; only five cases have been reported in the literature.
  • No mitotic activity or necrosis was seen in the tumor.
  • Immuhistochemically, the tumor cells positive for smooth muscle actin, vimentine, and S100 protein.
  • The diagnosis of benign myoepithelioma of the lung is so confirmed.
  • CONCLUSION: Benign myoepithelioma is a rare pulmonary neoplasm distinct from pleomorphic adenoma, which should be considered in the differential diagnosis of lung nodules.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2005 Nov;237(2):395-400 [16244247.001]
  • [Cites] Rev Pneumol Clin. 2004 Nov;60(5 Pt 1):282-4 [15687912.001]
  • [Cites] Lung Cancer. 1998 Apr;20(1):47-56 [9699187.001]
  • [Cites] Oncology. 1998 Sep-Oct;55(5):431-4 [9732221.001]
  • [Cites] Ultrastruct Pathol. 1995 Sep-Oct;19(5):335-45 [7483010.001]
  • [Cites] Histopathology. 1990 Oct;17(4):311-7 [2175294.001]
  • [Cites] Arch Pathol Lab Med. 1987 Nov;111(11):1082-5 [2821955.001]
  • [Cites] Am J Surg Pathol. 1984 Nov;8(11):803-20 [6209992.001]
  • [Cites] J Histochem Cytochem. 2003 Feb;51(2):133-9 [12533521.001]
  • [Cites] Chest. 2003 Jan;123(1 Suppl):89S-96S [12527568.001]
  • [Cites] Arch Pathol Lab Med. 2001 Nov;125(11):1494-6 [11698012.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Feb;17(2):187-9 [10731657.001]
  • (PMID = 20180958.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2828429
  •  go-up   go-down


58. Poujade O, Genin AS, Dhouha M, Luton D: A benign metastasizing leiomyoma involving a nodule in the pulmonary artery: case and literature review. Eur J Gynaecol Oncol; 2010;31(3):329-32
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A benign metastasizing leiomyoma involving a nodule in the pulmonary artery: case and literature review.
  • Benign metastasizing leiomyoma (BML) is a rare disease defined as a primary benign uterine tumor with "metastatic" lesions preferentially occurring in the lung, pelvis and lymph nodes.
  • The comparison of hysterectomy and lobectomy pieces showed a similar aspect, leading thus to the diagnosis of BML.
  • Awareness of this rare entity should potentially avoid under-diagnosis and difficulties due to hemorrhage during surgery.
  • [MeSH-major] Leiomyoma / pathology. Lung Neoplasms / secondary. Pulmonary Artery / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21077481.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


59. Yang YJ, Cheng DY, Fang X, Li XX: [The clinical diagnosis value of fibro-optic bronchoscope examination combined with tumor marker determination to lung cancer]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Mar;38(2):312-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical diagnosis value of fibro-optic bronchoscope examination combined with tumor marker determination to lung cancer].
  • OBJECTIVE: To investigate the diagnosis value of fibro-optic-bronchoscope combined with tumor maker determination to lung cancer.
  • METHODS: By fibro-optic bronchoscope (FB) and electrochemiluminescence (ECL) examinations, 98 cases with lung cancer and 88 cases with benign lung disease were studied for calculating the detectable sensitivity and specificity to lung cancer, then further for evaluating the clinical value of FB examination combined with detection of tumor marker in serum/pleural fluid of patients with lung cancer.
  • Results In patients with lung cancer, the serum levels of CEA, CA125 and CYFRA21-1 were (46.34 +/- 18.28) ng/mL, (83.34 +/- 33.26) U/mL and (25.67 +/- 10.32) ng/mL respectively, which were higher than those in patients with benign lung diseases.
  • The serum levels of above three tumor markers in patients with lung cancer all were significantly higher than those in patients with benign lung diseases (P < 0.05).
  • In the 36 specimens of pleural fluid, three tumor markers were higher than those in the corresponding serum samples.
  • The detectable sensitivity of each tumor marker in pleural fluid was higher than that in serum.
  • The sensitivity, specificity and overall accuracy of CEA in lung cancer were 37.5%, 87.5% and 63.6% respectively, of CA125 were 67.7%, 40.9% and 54.9%; of CYFRA21-1 were 56.3%, 81.8% and 68.5%; of FB were 60.4%, 100.0% and 79.4% respectively.
  • The sensitivity, specificity or overall accuracy of fibro-optic bronchoscope combined with tumor marker (TM) examination to diagnosis of lung cancer was 90.6%, 92.0% or 91.3% respectively.
  • CONCLUSION: The FB examination is valuable in diagnosing lung cancer, and by combined with TM determination, can further improve the accuracy to diagnosis of lung cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Bronchoscopy / methods. Lung Neoplasms / blood. Lung Neoplasms / diagnosis. Optical Fibers

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17441358.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


60. Takahashi Y, Fukusato T, Aita K, Toida S, Fukushima J, Imamura T, Tanaka F, Amano H, Takada T, Mori S: Solid pseudopapillary tumor of the pancreas with metastases to the lung and liver. Pathol Int; 2005 Dec;55(12):792-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid pseudopapillary tumor of the pancreas with metastases to the lung and liver.
  • After surgical resection of the pancreatic and liver tumors, liver nodules recurred repeatedly, and a solitary mass lesion occurred in the right lung.
  • Grossly, the pancreatic tumor was large and partially cystic.
  • Histologically, small and uniform tumor cells proliferated, having solid and pseudopapillary patterns.
  • These pathological findings enabled a pathological diagnosis of solid pseudopapillary tumor (SPT) of the pancreas to be made.
  • The pathological appearance of the liver and lung tumors was similar to that of the pancreatic tumor.
  • This is the first report of a case of pancreatic SPT that showed lung metastasis.
  • It should be kept in mind that pancreatic SPT may take such an aggressive clinical course, although they are usually benign in nature.
  • [MeSH-major] Cystadenocarcinoma, Papillary / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287495.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / beta Catenin
  •  go-up   go-down


61. van den Heuvel DA, Keijsers RG, van Es HW, Bootsma GP, de Bruin PC, Schramel FM, van Heesewijk JP: Invasive inflammatory myofibroblastic tumor of the lung. J Thorac Oncol; 2009 Jul;4(7):923-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive inflammatory myofibroblastic tumor of the lung.
  • Inflammatory myofibroblastic tumor (IMT) of the lung is a rare tumor but it should be considered when dealing with primary lung tumors in children, adolescents, and nonsmoking adults.
  • It is, from a pathologic point of view, a benign tumor composed of a spindle cell proliferation and inflammatory cells.
  • Its clinical behavior, however, is variable with a benign evolution at one, and a malignant evolution with recurrent and metastatic disease at the other end of the spectrum.
  • Diagnosis is very difficult and often only possible after resection of the tumor.
  • [MeSH-major] Granuloma, Plasma Cell / radiography. Granuloma, Plasma Cell / radionuclide imaging. Lung Neoplasms / radiography. Lung Neoplasms / radionuclide imaging
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Fluorodeoxyglucose F18. Humans. Male. Radiography, Thoracic. Radiopharmaceuticals. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19550247.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


62. Floyd HS, Farnsworth CL, Kock ND, Mizesko MC, Little JL, Dance ST, Everitt J, Tichelaar J, Whitsett JA, Miller MS: Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model. Carcinogenesis; 2005 Dec;26(12):2196-206
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model.
  • To determine the effects of expression of mutant Ki-ras on lung tumorigenesis, we developed a bitransgenic mouse model that expresses the human Ki-ras(G12C) allele in alveolar type II and/or Clara cells in a tetracycline-inducible, lung-specific manner.
  • Expression of Ki-ras(G12C) caused multiple, small lung tumors over a 12-month time period.
  • Although tumor multiplicity increased upon continued Ki-ras expression, most lung lesions were hyperplasias or well-differentiated adenomas.
  • This is in contrast to the more severe phenotypes observed in other transgenic mouse models in which different mutant Ki-ras alleles were expressed in the lung.
  • Withdrawal of doxycycline for 1 month resulted in almost a complete absence of proliferative pulmonary lesions, suggesting tumor regression in the absence of Ki-ras expression.
  • Mutant Ki-ras(G12C) expression was sufficient for initial lung tumor transformation, required for maintenance of tumor phenotype, and induced transformation of lung epithelial cells by the activation of multiple effector pathways.
  • These results describe a novel mouse lung tumor model demonstrating benign tumor development in the absence of tumor progression, which will provide a new tool for understanding the early stages of lung tumor pathogenesis.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - FVB-Tg(tetO/CMV-KRAS*G12C)9.1Msmi/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 1999 Nov;20(11):2159-65 [10545420.001]
  • [Cites] Trends Cell Biol. 2000 Apr;10(4):147-54 [10740269.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11858-64 [10766812.001]
  • [Cites] Lancet. 2000 Feb 5;355(9202):479-85 [10841143.001]
  • [Cites] Br J Cancer. 2000 Aug;83(4):473-9 [10945494.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Sep;279(3):L452-9 [10956619.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):38973-80 [10978313.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6551-8 [11641780.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3249-62 [11751631.001]
  • [Cites] Transgenic Res. 2002 Feb;11(1):21-9 [11874100.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 May;26(5):558-64 [11970907.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):22743-9 [11927601.001]
  • [Cites] J Pathol. 2002 Jul;197(4):527-35 [12115868.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10482-7 [12145322.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29510-8 [12039958.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):31808-17 [12082106.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):40231-8 [12885771.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):1050-9 [14593117.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):9-20 [14712206.001]
  • [Cites] Development. 2004 Feb;131(4):953-64 [14757645.001]
  • [Cites] Oncogene. 2004 Feb 5;23(5):1166-76 [14647414.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2307-16 [15059877.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):375-87 [15093544.001]
  • [Cites] Dev Dyn. 2004 Sep;231(1):57-71 [15305287.001]
  • [Cites] N Engl J Med. 1987 Oct 8;317(15):929-35 [3041218.001]
  • [Cites] Cancer Res. 1988 Oct 15;48(20):5738-41 [3048648.001]
  • [Cites] Mol Carcinog. 1990;3(5):287-95 [2244961.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1085-9 [1996309.001]
  • [Cites] Cancer Res. 1991 Mar 15;51(6):1744-8 [1998965.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 17;83(14):1024-7 [2072410.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1353-62 [1679529.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18):4999-5002 [1654209.001]
  • [Cites] Am J Physiol. 1991 Oct;261(4 Pt 1):L349-56 [1928370.001]
  • [Cites] Cancer Res. 1992 May 15;52(10):2903-6 [1581907.001]
  • [Cites] J Biol Chem. 1992 Jul 25;267(21):14703-12 [1634515.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5342-52 [1394139.001]
  • [Cites] Dev Biol. 1993 Apr;156(2):426-43 [8462742.001]
  • [Cites] Cancer Res. 1993 Apr 15;53(8):1743-6 [8467490.001]
  • [Cites] Oncogene. 1993 Sep;8(9):2407-12 [8395679.001]
  • [Cites] J Biol Chem. 1995 Feb 10;270(6):2689-94 [7852338.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1444-7 [7882350.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Feb;12(2):110-6 [7535083.001]
  • [Cites] Carcinogenesis. 1996 Jul;17(7):1519-26 [8706258.001]
  • [Cites] Exp Lung Res. 1997 Jan-Feb;23(1):35-49 [9028798.001]
  • [Cites] Cell. 1997 Mar 7;88(5):593-602 [9054499.001]
  • [Cites] Oncogene. 1997 May 29;14(21):2595-607 [9191059.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1163-8 [9214598.001]
  • [Cites] Oncogene. 1997 Sep 4;15(10):1151-9 [9294608.001]
  • [Cites] Oncogene. 1997 Oct 9;15(15):1781-6 [9362444.001]
  • [Cites] Exp Lung Res. 1998 Jul-Aug;24(4):541-55 [9659582.001]
  • [Cites] Clin Chem Lab Med. 1998 May;36(5):255-69 [9676381.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):411-8 [9816185.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2281-90 [10327074.001]
  • [Cites] Cytokine. 1999 Apr;11(4):305-12 [10328870.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Dec 15;201(3):295-302 [15582647.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):48-55 [15608639.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):13809-16 [15668254.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3155-62 [15867207.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • (PMID = 16051643.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / T32 ES007331; United States / NCI NIH HHS / CA / R01 CA91909; United States / NCI NIH HHS / CA / R01 CA091909-02; United States / NCI NIH HHS / CA / P30 CA12197; United States / NCI NIH HHS / CA / R01 CA091909-02S1; United States / NCI NIH HHS / CA / R01 CA091909; United States / NIEHS NIH HHS / ES / T32-ES07331; United States / NCI NIH HHS / CA / R01 CA091909-04S1; United States / NCI NIH HHS / CA / R01 CA091909-04; United States / NCI NIH HHS / CA / R01 CA091909-03S1; United States / NCI NIH HHS / CA / P30 CA012197; United States / NCI NIH HHS / CA / R01 CA091909-01A1; United States / NCI NIH HHS / CA / R01 CA091909-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; EC 2.7.1.- / MAP-kinase-activated kinase 2; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / RPS6KA1 protein, human; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 90-kDa; EC 2.7.11.1 / Rps6ka1 protein, mouse; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.6.5.2 / ral GTP-Binding Proteins; N12000U13O / Doxycycline
  • [Other-IDs] NLM/ NIHMS6241; NLM/ PMC1351110
  •  go-up   go-down


63. García-Reyna JC, Rico Martínez G, Vega González IF, Linares LM, Delgado Cedillo EA, Romero Ramírez R: [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin]. Acta Ortop Mex; 2008 Nov-Dec;22(6):390-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin].
  • [Transliterated title] 99mTc-Tetrofosmin en la evaluación de tumores musculoesqueléticos.
  • INTRODUCTION: (99m)Tc-tetrofosmin is an efficient agent as a tumor marker.
  • Several studies have proven its efficiency in detection and localization of tumors of the breast, larynx, thyroid, parathyroid glands, lung, brain, skin, lymphatic and musculoskeletal tissues with a sensitivity and specificity of 95% to 100%.
  • Nevertheless, benign pathology such as active inflammation is a source of false positives and the attending physician must consider the aid of complementary studies such as histopathology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280840.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


64. Paci M, Cavazza A, Annessi V, Ricchetti T, Rapicetta C, Sgarbi G: Cystic fibrohistiocytic tumor of the lung presenting as a solitary lesion. Rare Tumors; 2010;2(1):e14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic fibrohistiocytic tumor of the lung presenting as a solitary lesion.
  • Cystic fibrohistiocytic tumor of the lung is a rare neoplasm.
  • In many cases it represents a metastasis from a benign or low-grade fibrohistiocytic tumor of the skin, but occasionally it may be primary.
  • Microscopy of the apical segmentectomy showed a cystic fibrohistiocytic tumor, whereas the nodule of the lower lobe was an intraparenchymal lymph node.
  • The patient is alive with no tumor recurrence.
  • The differential diagnosis includes Langerhans cell histiocytosis, lymphangioleiomyomatosis, pleuropulmonary blastoma, and metastatic endometrial stromal sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139943.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994490
  • [Keywords] NOTNLM ; cystic fibrohistiocytic tumor / lung neoplasms / mesenchymal cystic hamartoma / mesenchymal tumors / metastases / pneumothorax
  •  go-up   go-down


65. Tatebe S, Oka K, Kuraoka S, Yatabe Y: Benign metastasizing leiomyoma of the lung: potential role of low-grade malignancy. Thorac Cardiovasc Surg; 2009 Apr;57(3):180-3
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign metastasizing leiomyoma of the lung: potential role of low-grade malignancy.
  • We report here 2 cases of multiple metastatic lung tumors after hysterectomy for leiomyoma.
  • One patient was diagnosed as having a benign metastasizing leiomyoma (BML), while the other patient simultaneously developed a left pelvic tumor and multiple lung tumors, both of which were finally diagnosed as low-grade endometrial stromal sarcomas (ESSs).
  • The metastatic potential of BML is not completely understood, but previously reported cases of BML may include low-grade ESS, which may play a significant role in the metastasis of benign uterine tumors.
  • [MeSH-major] Endometrial Neoplasms / pathology. Leiomyomatosis / pathology. Lung Neoplasms / secondary. Pelvic Neoplasms / pathology. Sarcoma, Endometrial Stromal / secondary. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19330762.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


66. Nuovo GJ, Schmittgen TD: Benign metastasizing leiomyoma of the lung: clinicopathologic, immunohistochemical, and micro-RNA analyses. Diagn Mol Pathol; 2008 Sep;17(3):145-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign metastasizing leiomyoma of the lung: clinicopathologic, immunohistochemical, and micro-RNA analyses.
  • Benign metastasizing leiomyomas are rare tumors, which are typically found in the lungs and, thus, might be confused with leiomyosarcomas.
  • Further, it is not clear whether the term "benign metastasizing leiomyoma" is a misnomer and whether these lesions actually represent low-grade malignant tumors that have a low proliferation index.
  • In this study, the histologic features, Ki67 index, p53, bcl-2, and miRNA expression were studied in 15 leiomyosarcomas (11 primary lesions and 4 metastases), 8 leiomyomas, and 10 cases of benign metastasizing leiomyoma (9 pulmonary lesions and 1 primary uterine lesion).
  • As expected, the Ki67 index for the benign metastasizing leiomyomas was equivalent to that for the leiomyomas and statistically less than that for the leiomyosarcomas.
  • The mean index was 2.3% (range: 0.9% to 8.8%) for the leiomyomas and 3.4% (range: 0.7% to 8.1%) for the benign metastasizing leiomyomas compared with 28.6% (range: 14.4% to 62.0%) for the leiomyosarcomas (P<0.025).
  • The miRNA, miR-221, which has been associated with a variety of cancers, was detected by in situ hybridization in 13/15 leiomyosarcomas, 0/8 leiomyomas, and 0/10 benign metastasizing leiomyomas.
  • In conclusion, benign metastasizing leiomyomas are indeed most likely benign lesions, and up-regulation of miR-221 expression is an accurate way to differentiate leiomyosarcoma from benign metastasizing leiomyoma.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):130-40 [16357844.001]
  • [Cites] Nat Methods. 2006 Jan;3(1):27-9 [16369549.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Surgery. 2006 Dec;140(6):899-905; discussion 905-6 [17188136.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1046-54 [17149698.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Apr;46(4):336-47 [17243163.001]
  • [Cites] Am J Surg Pathol. 2007 May;31(5):737-43 [17460458.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):126-8 [10665925.001]
  • [Cites] Br J Radiol. 2000 Apr;73(868):435-7 [10844871.001]
  • [Cites] Virchows Arch. 2000 Sep;437(3):284-92 [11037349.001]
  • [Cites] Cancer. 1975 Dec;36(6):2206-13 [1203871.001]
  • [Cites] Am J Surg Pathol. 1979 Aug;3(4):325-42 [395847.001]
  • [Cites] Virchows Arch. 1994;425(5):541-5 [7850080.001]
  • [Cites] Pathol Res Pract. 1996 Mar;192(3):215-23 [8739468.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):863-72 [9669348.001]
  • [Cites] Arch Pathol Lab Med. 1999 Oct;123(10):960-2 [10506455.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • (PMID = 18382364.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA114304; United States / NCI NIH HHS / CA / CA114304-03; United States / NCI NIH HHS / CA / R33 CA114304-03; United States / NCI NIH HHS / CA / R33 CA114304; United States / NCI NIH HHS / CA / CA114304
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / MIRN221 microRNA, human; 0 / MicroRNAs; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS199160; NLM/ PMC3038410
  •  go-up   go-down


67. Radulescu D, Pripon S, Ciuleanu TE, Radulescu LI: Malignant primary pulmonary tumor with hemangiopericytoma-like features: conventional hemangiopericytoma versus solitary fibrous tumor. Clin Lung Cancer; 2007 Sep;8(8):504-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant primary pulmonary tumor with hemangiopericytoma-like features: conventional hemangiopericytoma versus solitary fibrous tumor.
  • Although extremely rare, the primitive lung hemangiopericytoma in adults is similar to hemangiopericytomas with other soft tissue localizations.
  • Although generally benign and curable after radical surgery, it might also have a malignant clinical course with dissemination in both lungs, infiltration of vital organs (heart, pulmonary artery), extension to the adjacent tissues, and even pulmonary metastases.
  • The treatment of choice is the complete tumor resection with negative surgical margins after excision.
  • Over the years, the conventionally-defined hemangiopericytoma concept has evolved because of the nonspecific histologic growth pattern (characteristic monotonous appearance, moderate or high cellularity, and a well-developed branching vascular pattern) shared by numerous, unrelated benign or malignant lesions.
  • We report an uncommon case of primitive lung tumor exhibiting hemangiopericytoma-like features, with an aggressive, fatal clinical course.
  • Because of the major histologic overlap between solitary fibrous tumor and hemangiopericytoma and lack of clear classification criteria, we encountered difficulty in including this case in a known clinical entity; primitive solitary fibrous tumor of the lung, which mimics lung hemangiopericytoma, seemed to be the most plausible diagnosis.
  • [MeSH-major] Hemangiopericytoma / pathology. Lung Neoplasms / pathology. Solitary Fibrous Tumors / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922977.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Sheng SL, Huang G, Yu B, Qin WX: Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem; 2009 Sep;55(9):1656-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer.
  • Clinical significance of serum DKK1 in lung cancer remains to be determined.
  • By use of this method, we investigated the serum concentrations of DKK1 in 592 patients with malignancies, 72 patients with benign lung disease, and 120 healthy controls.
  • RESULTS: Serum DKK1 concentrations were significantly higher in patients with lung cancer than in patients with other malignant tumors or benign lung diseases and healthy controls.
  • Application of both DKK1 and cytokeratin 19 fragment increased sensitivity, correctly identifying 89.6% of the non-small cell lung cancer patients as positive.
  • The use of both DKK1 and neuron-specific enolase increased sensitivity to detect small cell lung cancer to 86.2%.
  • DKK1 concentrations increased with stage, tumor class, and presence of lymph node and distant metastases, regardless of histology and patient age and sex.
  • CONCLUSIONS: DKK1 was preferentially expressed in lung cancer.
  • Increasing concentrations of DKK1were significantly associated with tumor progression and decreased survival in patients with lung cancer. .
  • [MeSH-major] Biomarkers, Tumor / blood. Fluoroimmunoassay / methods. Intercellular Signaling Peptides and Proteins / blood. Lung Neoplasms / blood
  • [MeSH-minor] Aged. Calibration. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19628661.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


69. Chang T, Husain AN, Colby T, Taxy JB, Welch WR, Cheung OY, Early A, Travis W, Krausz T: Pneumocytic adenomyoepithelioma: a distinctive lung tumor with epithelial, myoepithelial, and pneumocytic differentiation. Am J Surg Pathol; 2007 Apr;31(4):562-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pneumocytic adenomyoepithelioma: a distinctive lung tumor with epithelial, myoepithelial, and pneumocytic differentiation.
  • Pulmonary tumors with epithelial and myoepithelial differentiation are rare, thought to be of bronchial minor salivary gland origin and classified similarly to salivary gland neoplasms.
  • We report a series of a distinctive subtype of pulmonary glandular tumors showing epithelial and myoepithelial differentiation with further pneumocytic specialization.
  • The tumors were grossly circumscribed, 0.8 to 2.6 cm in greatest dimension, and histologically showed glandular and spindle cell differentiation.
  • The biologic behavior to date has been benign.
  • This is the first reported series of a distinctive lung tumor with epithelial, myoepithelial, and pneumocytic differentiation that differs histologically from all previously recognized pulmonary salivary gland-type and pneumocytic tumors.
  • It is a unique benign appearing neoplasm for which the designation pneumocytic adenomyoepithelioma is suggested.
  • [MeSH-major] Lung Neoplasms / pathology. Myoepithelioma / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Microscopy, Electron, Transmission. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414103.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


70. Zarbis N, Barth TF, Blumstein NM, Schelzig H: Pecoma of the lung: a benign tumor with extensive 18F-2-deoxy-D-glucose uptake. Interact Cardiovasc Thorac Surg; 2007 Oct;6(5):676-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pecoma of the lung: a benign tumor with extensive 18F-2-deoxy-D-glucose uptake.
  • A case of lung pecoma (i.e. tumors showing perivascular epithelioid cell differentiation) with extensive 18F-2-deoxy-D-glucose (FDG) uptake in PET/CT study is reported.
  • Pecomas of the lung--which include the better known clear cell 'sugar' tumor--are a subset of extremely rare lung tumors which usually react positively to both melanocytic and smooth muscle markers.
  • Although widely presumed as benign in computed tomography (CT) and positron emission tomography (PET)/CT studies they depict as malignant, thus complicating the preoperative diagnosis.
  • [MeSH-major] Cell Differentiation. Epithelioid Cells / pathology. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17670735.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


71. Markert E, Gruber-Moesenbacher U, Porubsky C, Popper HH: Lung osteoma--a new benign lung lesion. Virchows Arch; 2006 Jul;449(1):117-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung osteoma--a new benign lung lesion.
  • Extraskeletal osteomas have not been described in the lung.
  • Tumors with osseous elements can be found, such as hamartoma and amyloid tumor, and reactive lesions such as osseous metaplasia.
  • A 39-year-old male patient was treated for multiple myeloma and got a bone marrow transplantation 2 years and a few months before he presented with a solitary well-circumscribed tumor in the right middle lobe.
  • The tumor presented with a fibrous capsule and consisted of mature bone trabecules.
  • Within the tumor, fatty tissue was seen.
  • No amyloid deposition, no immature epithelial tubules as in hamartomas, and no normal lung structure as in osseous metaplasia were seen.
  • To the best of our knowledge, this is the first case of an osteoma being reported in the lung looking like any other extraskeletal osteoma.
  • This tumor might have been induced by circulating stem cells; however, due to autologous bona marrow transplantation, this cannot be proven.
  • [MeSH-major] Bone Neoplasms / pathology. Lung Neoplasms / pathology. Neoplasms, Second Primary / pathology. Ossification, Heterotopic / pathology. Osteoma / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Bone Marrow Transplantation. Diagnosis, Differential. Hamartoma / diagnosis. Humans. Immunohistochemistry. Male. Multiple Myeloma / pathology. Multiple Myeloma / therapy. Osteonectin / analysis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639606.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Osteonectin
  •  go-up   go-down


72. Hsuan CF, Tseng WK, Yang CH, Lee TL, Hu PY, Wu CC: Primary myxosarcoma of the right inferior pulmonary vein presenting clinically as benign left atrial myxoma with a concurrent right lower lung tumor. Circ J; 2009 Aug;73(8):1547-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary myxosarcoma of the right inferior pulmonary vein presenting clinically as benign left atrial myxoma with a concurrent right lower lung tumor.
  • Although myxomas are the most common intracavitary tumor of the left atrium, some findings should alert the clinician to the probability of malignancy.
  • She was preoperatively diagnosed as left atrial myxoma with a concurrent right lower lung tumor.
  • [MeSH-major] Lung Neoplasms / complications. Myxoma / diagnosis. Myxosarcoma / complications. Myxosarcoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Heart Atria / pathology. Humans. Pulmonary Veins / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19139592.001).
  • [ISSN] 1347-4820
  • [Journal-full-title] Circulation journal : official journal of the Japanese Circulation Society
  • [ISO-abbreviation] Circ. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


73. Arif S, Ganesan R, Spooner D: Intravascular leiomyomatosis and benign metastasizing leiomyoma: an unusual case. Int J Gynecol Cancer; 2006 May-Jun;16(3):1448-50
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular leiomyomatosis and benign metastasizing leiomyoma: an unusual case.
  • Benign metastasizing leiomyoma (BML) and intravascular leiomyomatosis (IVL) are rare variants of uterine leiomyomas.
  • The remaining tumor was treated with a gonadotrophin-releasing hormone agonist, resulting in significant reductions in tumor size.
  • It was concluded that the lesions in the lungs were an example of BML arising from the initial diagnosis of uterine leiomyoma, and the caval lesion was an IVL.
  • Long-term follow-up is recommended, and familiarity with rare forms of benign smooth muscle uterine tumors is essential in avoiding misdiagnosis and overtreatment.
  • [MeSH-major] Leiomyoma / diagnosis. Leiomyomatosis / diagnosis. Uterine Neoplasms / pathology. Vascular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803546.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Meng YH, Yu JY, Lu YL, Zhu YJ, Zhang JQ, Ning HY, Hu M, Liu X, Kang XL, Duan W: [Expression of PAR-1 in human lung carcinoma and its relationship with tumor metastatic potential]. Zhonghua Bing Li Xue Za Zhi; 2006 Jan;35(1):24-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of PAR-1 in human lung carcinoma and its relationship with tumor metastatic potential].
  • OBJECTIVE: To explore the correlation between expression of PAR-1 and metastasis of human lung carcinoma.
  • METHODS: Expression levels of PAR-1 were examined in surgically resected lung carcinoma specimens and corresponding lymph nodes by RT-PCR and immunohistochemistry, combined with morphometric methodology and clinicopathologic profiles.
  • The percentage of PAR-1 protein expression cells was significantly higher in tumors with metastasis (85.7%, 48/56) than those without (45.8%, 11/24).
  • Morphometric study demonstrated that there were significant differences of PAR-1 protein expression levels between tumors with metastatic and those without, primary and metastatic carcinomas, primary carcinomas and benign lung tissues adjacent to the carcinoma.
  • No significant correlation was found between PAR-1 expression level and tumor size, histological types and tumor grades.
  • CONCLUSION: PAR-1 expression may play an important role in determining the malignant phenotypes of lung cancers and significantly contribute to their initiation, progression and metastasis.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Receptor, PAR-1 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608645.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptor, PAR-1
  •  go-up   go-down


75. Antic T, Kapur U, Vigneswaran WT, Oshima K: Inflammatory sarcomatoid carcinoma: a case report and discussion of a malignant tumor with benign appearance. Arch Pathol Lab Med; 2005 Oct;129(10):1334-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory sarcomatoid carcinoma: a case report and discussion of a malignant tumor with benign appearance.
  • Inflammatory sarcomatoid carcinoma is an aggressive tumor with an unusually benign appearance.
  • We report the case of a 65-year-old man with a history of inoperable poorly differentiated carcinoma of the right lung, for which he had received chemoradiotherapy.
  • A new solitary mass was discovered 4 years later in the left lung on surveillance computed tomography.
  • In contrast to sarcomatoid carcinomas, this case highlights the deceptively benign appearance of inflammatory sarcomatoid carcinoma.
  • This leads us to concur with the recommendation to exercise caution when attempting the diagnosis of apparently benign lesions on intraoperative frozen section in patients with high clinical suspicion of malignancy.
  • [MeSH-major] Carcinosarcoma / pathology. Lung Neoplasms / pathology. Plasma Cell Granuloma, Pulmonary / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Bronchiolitis Obliterans / diagnosis. Diagnosis, Differential. Humans. Lymphomatoid Granulomatosis. Male. Neoplasm Invasiveness. Neoplasms, Second Primary. Pneumonia / diagnosis. Sarcoma / diagnosis. Sarcoma / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16196527.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 16
  •  go-up   go-down


76. Qu YM, Liao GQ, Liu PH, Wang HM, Liu L, Li LL, Xie GQ: [Clinical significance of expressions of tumor markers in peripheral blood in non-small cell lung cancer]. Zhonghua Yi Xue Za Zhi; 2010 Jul 27;90(28):1958-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of expressions of tumor markers in peripheral blood in non-small cell lung cancer].
  • OBJECTIVE: To investigate the expressions of BJ-TSA-9, CK19 and Pre-proGRP mRNA in peripheral blood from the patients with non-small cell lung cancer and analyze their correlations with non-small cell lung cancer.
  • METHODS: The expressions of BJ-TSA-9, CK19 and Pre-proGRP mRNA were detected by nested reverse transcription-PCR assay in peripheral blood from the patients with non-small cell lung cancer (n = 120), benign pulmonary disease (n = 106) and from healthy subjects (n = 80) so as to further investigate their relationship with clinicopathological features and prognosis.
  • RESULTS: The expressions of BJ-TSA-9, CK19 and Pre-proGRP mRNA in non-small cell lung cancer patients were 56.7%, 57.5%, 35.0%, higher than that of benign pulmonary disease (0.9%, 6.6%, 5.7%) and healthy groups (0, 3.8%, 0, all P < 0.05).
  • CONCLUSION: BJ-TSA-9, CK19 and Pre-proGRP mRNA may be the specific and sensitive markers to detect circulating tumor cells in the peripheral blood of non-small cell lung cancer patients.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. Lung Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Keratin-19 / blood. Male. Middle Aged. Neoplasm Proteins / blood. Neoplasm Staging. Peptides / blood. Prognosis. Protein Precursors / blood. RNA, Messenger / genetics. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979858.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FAM83A protein, human; 0 / Keratin-19; 0 / Neoplasm Proteins; 0 / Peptides; 0 / Protein Precursors; 0 / RNA, Messenger; 0 / gastrin-releasing peptide precursor
  •  go-up   go-down


77. Floyd HS, Jennings-Gee JE, Kock ND, Miller MS: Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice. Mol Carcinog; 2006 Jul;45(7):506-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice.
  • Mutations in Ki-ras occur in approximately 30-50% of patients with adenocarcinoma (AC) of the lung.
  • We previously reported the development of a bitransgenic mouse model that expressed the human Ki-ras(G12C) allele in a lung-specific, tetracycline-inducible manner and gave rise to benign lung tumors.
  • In the current study, these benign tumors, which represent relatively early lesions in neoplastic progression, were analyzed for molecular alterations secondary to mutant Ki-ras expression to determine the gene(s) that contribute to adenoma (AD) development.
  • Tumors were removed following doxycycline (DOX) treatment for 9 and 12 mo and examined for alterations in cell-cycle regulatory genes.
  • All of the tumors examined exhibited a mean reduction of approximately fivefold for the retinoblastoma gene (P < 0.02).
  • Increased expression of both p19(Arf) and survivin were detected in a majority of the tumors examined (P < 0.01 and 0.001, respectively), but no change in cyclin D1 RNA expression was observed.
  • A subset of the lung tumors (8/28) displayed reduced levels of p16(Ink4a) expression (P = 0.02).
  • Immunohistochemical analysis confirmed the upregulation of p19(Arf) and survivin in all 10 of the lung tumors examined.
  • However, increased staining for cyclin D1 was observed in the tumor tissue.
  • In addition, increased levels of activated p53 were found in lung tumor tissues stained with an anti-phospho-p53 antibody, while an absence of staining was observed with an anti-phospho-pRb antibody in both normal control and tumor tissue.
  • Analysis of the methylation status of p16(Ink4a) by methylation-specific PCR (MSP) demonstrated that seven of eight tumors exhibiting decreased expression of p16(Ink4a) had at least partial methylation of the promoter region.
  • These data thus identify alterations in specific genes and pathways that combine with the mutation in Ki-ras to promote the formation of benign lung tumors and suggest potential targets for the development of novel chemotherapeutic and chemopreventive agents during the early stages of lung tumor progression.
  • [MeSH-major] Genes, ras / genetics. Lung Neoplasms / genetics. Polymorphism, Single Nucleotide. ras Proteins / genetics
  • [MeSH-minor] Animals. Base Sequence. Cell Cycle / genetics. Cyclin D1 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Primers. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Disease Models, Animal. Humans. Mice. Mice, Transgenic. Retinoblastoma Protein / genetics


78. Glaab R, Turina M, Achermann E, Maurer R, Went P, Schöb O: [Alveolar adenoma--a rare pulmonary mass: case report and review of the literature]. Zentralbl Chir; 2009 Sep;134(5):478-80
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Definitive histology following thoracoscopic wedge resection showed the distinctive findings of an alveolar adenoma, a very rare benign tumour of the lung of unknown histogenesis.
  • Its histological features, the benign proliferation of alveolar epithelium and septal mesenchyme, allow for its distinction from other benign lesions of the lung.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Bronchogenic / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Hemoptysis / etiology. Humans. Lung / pathology. Male. Middle Aged. Phlebography. Pneumonectomy. Thoracoscopy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag Stuttgart-New York.
  • (PMID = 19757349.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 5
  •  go-up   go-down


79. Gu M, Sohn K, Kim D, Kim B: Metastasizing dermatofibroma in lung. Ann Diagn Pathol; 2007 Feb;11(1):64-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasizing dermatofibroma in lung.
  • Benign dermatofibroma is very common skin tumor and can very rarely metastasize.
  • We report a case of metastasizing dermatofibroma on a 36-year-old woman who presented multiple bilateral lung nodules.
  • Chest computed tomographic scanning shows multiple nodules in both lung fields.
  • The tumor cells stained for CD68 and CD10.
  • The lung mass shows same histologic features with skin lesion.
  • [MeSH-major] Histiocytoma, Benign Fibrous / secondary. Lung Neoplasms / secondary. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Dermatofibroma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17240311.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; EC 3.4.24.11 / Neprilysin
  • [Number-of-references] 7
  •  go-up   go-down


80. Hirata T, Otani T, Minamiguchi S: Clear cell tumor of the lung. Int J Clin Oncol; 2006 Dec;11(6):475-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell tumor of the lung.
  • Clear cell tumor of the lung is a rare benign tumor.
  • We report herein a case of clear cell tumor of the lung.
  • Investigation with abdominal CT scans showed no evidence of renal disease, and the tumor was diagnosed as clear cell tumor of the lung.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Lung Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17180518.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


81. Hanley KZ, Facik MS, Bourne PA, Yang Q, Spaulding BO, Bonfiglio TA, Xu H: Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer; 2008 Feb 25;114(1):49-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
  • Using a mouse monoclonal antibody (L523S) against KOC, KOC expression was investigated in malignant tumors and reactive mesothelial cells in serous effusions.
  • METHODS: Seventy-six cases with paraffin-embedded pleural, pericardial, and peritoneal serous effusion cell blocks including 60 malignant serous effusions (11 malignant pleural mesotheliomas and 49 metastatic carcinomas) and benign pleural effusions (14 cases with reactive mesothelial cells and 2 cases with atypical cells with uncertain significance) were selected for immunohistochemical analysis with L523S, calretinin, and CK5/6.
  • Interestingly, 3 of 16 cases exhibited various degrees of positivity for KOC, 2 of which were diagnosed as lung adenocarcinoma with a recurrence after tumor resection and 1 as malignant pleural mesothelioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Mesothelioma / diagnosis. Neoplasm Proteins / analysis. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis. RNA-Binding Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ascitic Fluid / chemistry. Calbindin 2. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Pericardial Effusion / chemistry. S100 Calcium Binding Protein G / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society
  • (PMID = 18098206.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calb2 protein, mouse; 0 / Calbindin 2; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


82. Liang Z, Wang HF, Wu AZ, Cai JH: [Clinical value of multi-tumor markers protein biochip in the diagnosis of pulmonary carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Nov;30(11):2516-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value of multi-tumor markers protein biochip in the diagnosis of pulmonary carcinoma].
  • OBJECTIVE: To assess the value of multi-tumor markers protein biochip in the diagnosis and therapy of pulmonary carcinoma.
  • METHODS: Twelve tumor markers (CA199, NSE, CEA, CA242, Ferrtin, β-HCG, AFP, f-PSA, PSA, CA125, HGH, and CA153) were detected using protein chip in 308 patients with pulmonary carcinoma, 218 with benign lung lesions and 250 healthy subjects.
  • RESULTS: The positivity rate was 72.4% in pulmonary carcinoma cases, obviously higher than that in the benign cases (22.0%, P<0.01) and healthy subjects (5.6%, P<0.01).
  • CONCLUSION: Protein biochip containing multiple tumor markers provides valuable assistance in the diagnosis and therapeutic effect monitoring of pulmonary carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Lung Neoplasms / diagnosis. Protein Array Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21097421.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


83. Lan L, Sun T, Liu D, Pang J, Yang L, Yang C, Xiong D: [Expression of ezrin in human lung carcinoma and its clinicopathologic significance.]. Zhongguo Fei Ai Za Zhi; 2008 Feb 20;11(1):67-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of ezrin in human lung carcinoma and its clinicopathologic significance.].
  • BACKGROUND: Metastasis is the main cause of cancer related mortality, and identification of genes involved in tumor metastasis is important for effective therapies.
  • The membrane cytoskeletal crosslinker participated in several functions including cell adhersion, motility and cell survival, and there is increasing evidence that it regulates tumor progression.
  • However, the role played by ezrin in lung cancer metastasis has not been clearly delineated.
  • The aims of this study are to investigate the ezrin expression pattern in human lung carcinoma and the correlation with clinicopathologic characteristics.
  • METHODS: Ezrin expression was detected by two- step immunohistochemical staining technique in tumor tissues from 75 lung cancer cases and in normal lung tissues from 16 cases with benign disease and analyzed by the lung cancer clinicopathologic characteristics.
  • The gene and protein level expression of Ezrin in lung cancer cell lines was also detected by Confocal Laser Scanning Microscope (CLSM) and RT-PCR.
  • RESULTS: The positive incidence of ezrin expression (77.3%) was significantly lower in lung cancer tissues than that in normal tissues (100%) (P<0.05), and the down-regulated of ezrin expression was significantly correlated with lymph node metastasis and distant metastasis (P<0.05) and was not correlated with gender, age, tumor size, pathological type, the degree of differentiation of tissue and clinical stage.
  • CONCLUSIONS: Ezrin expression is down-regulated in lung cancer tissue and lung cancer cell line, and the locational change from cell membrane to cell plasma may be associated with the oncogenesis and development of lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20727270.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


84. Choi US, Alleman AR, Choi JH, Kim HW, Youn HJ, Lee CW: Cytologic and immunohistochemical characterization of a lung carcinoid in a dog. Vet Clin Pathol; 2008 Jun;37(2):249-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic and immunohistochemical characterization of a lung carcinoid in a dog.
  • An 11-year-old neutered male Yorkshire Terrier was presented to the Haemaru Referral Animal Hospital with a history of unresponsive tracheal collapse and an incidental finding of a lung nodule in the left caudal lung lobe on radiography.
  • A caudal lung lobectomy was performed, and histologic evaluation of the mass revealed round to polygonal cells with abundant eosinophilic granular cytoplasm and round nuclei with mild anisokaryosis and 0-3 mitotic figures per high-power field.
  • Cells were arranged in packets separated by fine fibrovascular stroma, suggestive of a pulmonary neuroendocrine neoplasm, specifically a carcinoma/carcinoid.
  • With these findings the tumor was diagnosed as a primary lung carcinoid.
  • Eleven months after resection, there was no evidence of tumor regrowth or metastasis.
  • The absence of necrosis, few mitotic figures, minimal pleomorphism, and benign behavior of this tumor resembled those of a typical carcinoid in humans.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533928.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Granberg D, Wilander E, Oberg K: Expression of tyrosine kinase receptors in lung carcinoids. Tumour Biol; 2006;27(3):153-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of tyrosine kinase receptors in lung carcinoids.
  • OBJECTIVES: Typical lung carcinoids are usually relatively benign tumors, but distant metastases are seen in up to 12% of the patients.
  • In contrast, atypical carcinoids are more aggressive tumors, displaying metastases in up to 70%.
  • The current treatment of metastatic lung carcinoids is discouraging.
  • New therapies, such as inhibitors of the tyrosine kinase receptor family c-kit, platelet-derived growth factor receptors (PDGFR) alpha and beta and epidermal growth factor receptor (EGFR) have shown promising results in other malignancies and might be of value in malignant lung carcinoids.
  • PATIENTS AND METHODS: Tumor tissue from 51 patients with typical lung carcinoids were immunostained with polyclonal antibodies against c-kit, PDGFRalpha, PDGFRbeta and EGFR.
  • RESULTS: Twelve of the tumors stained positive for c-kit, 44 expressed PDGFRalpha, 30 showed positive immunoreactivity for PDGFRbeta and 26 were EGFR immunoreactive.
  • Among the 17 patients with distant metastases, 5 tumors expressed c-kit, 12 were PDGFRalpha immunoreactive, 9 stained positive for PDGFRbeta, and 7 showed positive immunoreactivity for EGFR.
  • CONCLUSIONS: Tyrosine kinase receptors such as c-kit, PDGFRalpha, PDGFRbeta and EGFR are expressed in a significant number of patients with metastatic lung carcinoids.
  • [MeSH-major] Carcinoid Tumor / diagnosis. Lung Neoplasms / diagnosis. Receptor Protein-Tyrosine Kinases / analysis

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612146.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


86. Lazaretti NS, Dallagasperina VW, Villaroel RU, Schlittler LA: [Giant cell tumour of distal femur with pulmonary metastases]. Rev Port Pneumol; 2010 Mar-Apr;16(2):331-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant cell tumour of distal femur with pulmonary metastases].
  • [Transliterated title] Tumor de células gigantes de fémur distal com metástases pulmonares.
  • Gian cell is normally a benign primary skeletal lesion located in the epiphysis of the long bones.
  • It is more frequente in the third and fourth decades of life but can exhibit the behaviour of a malignant tumour with distal metatasis.
  • Up to 10% of patients present distal metatasis, usually in the lung, and it is concomitant to recurrence in the primary site.
  • The treatment of primary tumour is extensive surgical resection.
  • We report a case of a 35-year-old patient with lung metatases 21 months after curettage of giant cell tumour in distal femur.
  • [MeSH-major] Femoral Neoplasms / pathology. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20437009.001).
  • [ISSN] 2172-6825
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


87. Bilaceroglu S, Gursoy S, Yücel N, Ozbilek E: Inflammatory myofibroblastic tumor presenting as a large mass and a spontaneously resolving nodule in the lung. J Bronchology Interv Pulmonol; 2009 Oct;16(4):286-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor presenting as a large mass and a spontaneously resolving nodule in the lung.
  • Earlier diagnostic work-ups had been inconclusive, and she was referred for the evaluation of the bilateral lung lesions as seen on her chest x-ray.
  • Ultrasonography-guided transthoracic cutting needle biopsy of the right-sided mass and following right lower lobectomy both yielded benign specimens pathologically assessed as "inflammatory myofibroblastic tumor."

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23168596.001).
  • [ISSN] 1944-6586
  • [Journal-full-title] Journal of bronchology & interventional pulmonology
  • [ISO-abbreviation] J Bronchology Interv Pulmonol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Charalabopoulos K, Karakosta A, Bablekos G, Golias C, Charalabopoulos A, Tsanou E, Peschos D, Zoganas L, Batistatou A: CEA levels in serum and BAL in patients suffering from lung cancer: correlation with individuals presenting benign lung lesions and healthy volunteers. Med Oncol; 2007;24(2):219-25
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEA levels in serum and BAL in patients suffering from lung cancer: correlation with individuals presenting benign lung lesions and healthy volunteers.
  • BACKGROUND: Carcinoembryonic antigen (CEA) is a tumor marker belonging to the immunoglobulin gene superfamily of adhesion molecules.
  • CEA is synthesized by epithelial and tumor cells.
  • In this study, CEA levels in sera and bronchoalveolar lavage fluid (BAL) were measured in patients with malignant lung cancer and benign lung diseases.
  • Fifty patients with lung cancer (G1), 20 patients with benign lung lesions (G2), and a control group consisted of 20 individuals (G3) were enrolled in the study.
  • CONCLUSIONS: CEA levels in BAL of normal individuals may be influenced by smoking and other factors that affect lung epithelial cell function.
  • Thus, CEA measurement in BAL alone has little value in the diagnosis of malignancy.
  • Smokers of G2 have to be followed up carefully for the possibility of lung cancer growth.
  • [MeSH-major] Bronchoalveolar Lavage Fluid / chemistry. Carcinoembryonic Antigen / analysis. Lung Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848747.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


89. Sidiropoulou N, Filippousis P, Apostolopoulou S, Tsangaridou I, Thanos L: Tumor-like pulmonary sarcoidosis diagnosed by CT-guided transthoracic lung biopsy. Cases J; 2009;2:6607

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-like pulmonary sarcoidosis diagnosed by CT-guided transthoracic lung biopsy.
  • INTRODUCTION: Most patients referred for lung biopsy have a focal lesion that is likely to be a carcinoma and fine needle aspiration (FNA) is usually sufficient to confirm diagnosis.
  • Chest X-ray and CT scan revealed multiple masses in both lungs suggesting lung metastasis.
  • None of the laboratory examinations revealed any primary extrapulmonary tumor.
  • Histopathological examination confirmed the diagnosis of sarcoidosis.
  • CONCLUSION: CT-guided core needle biopsy is a very helpful diagnostic tool in order to determine the benign or malignant nature of a thoracic lesion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Med Assoc. 1954 May 1;155(1):21-4 [13151881.001]
  • [Cites] Am J Surg. 1970 Nov;120(5):637-43 [5313967.001]
  • [Cites] AJR Am J Roentgenol. 1997 Sep;169(3):661-6 [9275873.001]
  • [Cites] Chest. 1997 Jun;111(6):1615-21 [9187184.001]
  • [Cites] Postgrad Med J. 1996 Apr;72(846):196-200 [8733524.001]
  • [Cites] Clin Radiol. 1996 Jul;51(7):503-6 [8689827.001]
  • [Cites] Radiology. 1996 Mar;198(3):715-20 [8628859.001]
  • [Cites] Acta Radiol. 1994 May;35(3):251-4 [8192962.001]
  • [Cites] Am Rev Respir Dis. 1989 Jul;140(1):255-6 [2751170.001]
  • [Cites] AJR Am J Roentgenol. 1988 Nov;151(5):903-7 [3263019.001]
  • [Cites] Radiology. 1987 Feb;162(2):389-91 [3797651.001]
  • [Cites] Radiology. 1970 Jul;96(1):47-8 [5420410.001]
  • [Cites] Chest. 1974 Aug;66(2):216-8 [4853575.001]
  • [Cites] Am Rev Respir Dis. 1972 Aug;106(2):186-93 [5049652.001]
  • [Cites] Clin Chest Med. 1997 Dec;18(4):695-706 [9413653.001]
  • (PMID = 19829830.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2740031
  •  go-up   go-down


90. Giulianotti PC, Buchs NC, Caravaglios G, Bianco FM: Robot-assisted lung resection: outcomes and technical details. Interact Cardiovasc Thorac Surg; 2010 Oct;11(4):388-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robot-assisted lung resection: outcomes and technical details.
  • From June 2001 to June 2009, 38 consecutive totally robotic lung resections were performed in two different hospitals by a single surgeon.
  • The indication was a malignant tumor in 28 cases.
  • There were nine cases with benign pathology.
  • In this heterogeneous series of lung resections, we report low mortality and morbidity.
  • [MeSH-major] Lung Neoplasms / surgery. Pneumonectomy. Robotics
  • [MeSH-minor] Humans. Lung Diseases / surgery. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20634275.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


91. Islam S, Roustan Delatour NL, Salahdeen SR, Mai KT, Senterman M, Mokhtar GA: Cytologic features of benign solitary pulmonary nodules with radiologic correlation and diagnostic pitfalls: a report of six cases. Acta Cytol; 2009 Mar-Apr;53(2):201-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic features of benign solitary pulmonary nodules with radiologic correlation and diagnostic pitfalls: a report of six cases.
  • The majority of SPNs represent benign processes, including granulotmatous inflammation, bronchogenic cysts and hamartomata.
  • However, a solitary nodule may also potentially represent an early stage of lung cancer or a metastasis.
  • CASES: We report the cytologic features of 6 cases of benign SPN: exogenous lipid pneumonia, sclerosing hemangioma, hemartoma, bronchogenic cyst, fungal granuloma and solitary fibrous tumor.
  • CONCLUSION: Cytologically, lack of nuclear atypia with bland chromatin is useful in separating benign from malignant SPN.
  • Radiologically, smaller lesions with smooth, well-defined margins and calcifications are more likely to be benign.
  • Our cases illustrate the cytologic and immunohistochemical features that can help to make a more precise diagnosis.
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Bronchogenic Cyst / pathology. Bronchogenic Cyst / radiography. Female. Granuloma / microbiology. Granuloma / pathology. Granuloma / radiography. Hamartoma / pathology. Hamartoma / radiography. Humans. Immunohistochemistry. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Male. Middle Aged. Mycoses / pathology. Mycoses / radiography. Pneumonia, Lipid / pathology. Pneumonia, Lipid / radiography. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365977.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Edelweiss M, Gupta N, Resetkova E: Preoperative diagnosis of clear cell "sugar" tumor of the lung by computed tomography-guided fine-needle biopsy and core-needle biopsy. Ann Diagn Pathol; 2007 Dec;11(6):421-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative diagnosis of clear cell "sugar" tumor of the lung by computed tomography-guided fine-needle biopsy and core-needle biopsy.
  • Clear cell "sugar" tumor (CCST) of the lung is a very rare benign neoplasm believed to arise from epithelioid cells of perivascular differentiation.
  • This tumor is typically diagnosed by thoracotomy.
  • We here depict an additional case of CCST of the lung that was preoperatively diagnosed by computed tomography-guided transthoracic fine-needle aspiration biopsy and core-needle biopsy.
  • We underscore the importance of cytologic and histologic correlation and the role of ancillary studies in differentiating this lesion from other primary or metastatic clear cell tumors of the lung.
  • [MeSH-major] Lung Neoplasms / pathology. Radiography, Interventional
  • [MeSH-minor] Back Injuries / surgery. Biopsy, Needle. Diagnosis, Differential. Epithelioid Cells / pathology. Humans. Hypertension / complications. Immunohistochemistry. Laminectomy. Male. Middle Aged. Smoking / adverse effects. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18022127.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Thacker MM, Humble SD, Mounasamy V, Temple HT, Scully SP: Case report. Granular cell tumors of extremities: comparison of benign and malignant variants. Clin Orthop Relat Res; 2007 Feb;455:267-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report. Granular cell tumors of extremities: comparison of benign and malignant variants.
  • Granular cell tumors are uncommon soft tissue neoplasms that arise from cells of neural origin.
  • We present three patients with this rare tumor: one with a benign tumor, one with a malignant tumor, and one with a histologically benign tumor that later metastasized to the lung.
  • We studied the difficulty in differentiating between the benign and malignant variants using only histology.
  • [MeSH-major] Granular Cell Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936589.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. ZHANG Y, LI M, LIU Y, HAN N, ZHANG K, XIAO T, CHENG S, GAO Y: [ENO1 protein levels in the tumor tissues and circulating plasma samples of non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi; 2010 Dec;13(12):1089-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [ENO1 protein levels in the tumor tissues and circulating plasma samples of non-small cell lung cancer patients].
  • BACKGROUND AND OBJECTIVE: proper tumor markers are useful to diagnosis, prognosis and treatment for lung cancer.
  • The aim of this study is to examine the levels of alpha-enolase (ENO1) protein in the tumor tissues and peripheral plasma samples obtained from non-small cell lung cancer (NSCLC) patients, and evaluate its potential clinical significance.
  • METHODS: the ENO1 protein levels in the tumor tissues and corresponding normal tissues from 16 cases of lung squamous cell carcinoma were analyzed by Western blot.
  • The ENO1 protein levels in the plasma samples from 42 healthy individuals, 34 patients with lung benign disease and 84 patients with NSCLC were measured by double antibody sandwich enzyme-linked immunosorbent assay.
  • RESULTS: for 87.5% (14/16) of the patients with lung squamous cell carcinoma, the ENO1 protein level in the tumor tissues was higher than that in the corresponding normal lung tissues.
  • The ENO1 protein level in the plasma of NSCLC patients was significantly higher than that in the plasma of healthy individuals (P=0.031) and patients with lung benign disease (P=0.019).
  • Furthermore, the ENO1 protein level was significantly higher in the plasma of patients with lung adenocarcinoma than that of patients with lung squamous cell carcinoma.
  • CONCLUSIONS: the elevated levels of ENO1 protein in the tumor tissues and the plasma samples from NSCLC patients indicate ENO1 may be a candidate biomarker of lung cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / metabolism. DNA-Binding Proteins / blood. DNA-Binding Proteins / metabolism. Phosphopyruvate Hydratase / blood. Phosphopyruvate Hydratase / metabolism. Tumor Suppressor Proteins / blood. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21159241.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 4.2.1.11 / ENO1 protein, human; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


95. Kwon YI, Kim TH, Sohn JW, Yoon HJ, Shin DH, Park SS: Benign pulmonary metastasizing leiomvomatosis: case report and a review of the literature. Korean J Intern Med; 2006 Sep;21(3):173-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign pulmonary metastasizing leiomvomatosis: case report and a review of the literature.
  • An open lung biopsy revealed tumor that was composed of interlacing bundles of spindle cells with cigar shaped nucleus and eosinophilic myofibrils in the cytoplasm; consistent with multiple leiomyomas.
  • During the open lung biopsy procedure, all the nodules were excised.
  • We report here on an interesting case of benign metastasizing leiomyoma (BML) in 51-year-old patient.
  • [MeSH-major] Leiomyomatosis / pathology. Lung Neoplasms / secondary. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Jan;31(1):126-8 [10665925.001]
  • [Cites] Arch Pathol Lab Med. 1999 Oct;123(10):960-2 [10506455.001]
  • [Cites] Virchows Arch. 2000 Sep;437(3):284-92 [11037349.001]
  • [Cites] Chirurg. 2001 Mar;72(3):308-11 [11317453.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jun;176(6):1409-13 [11373202.001]
  • [Cites] Am J Clin Oncol. 2003 Oct;26(5):473-6 [14528073.001]
  • [Cites] Acta Oncol. 2004;43(1):113-4 [15068329.001]
  • [Cites] Cancer. 1977 Jan;39(1):314-21 [318914.001]
  • [Cites] Ann Chir Gynaecol. 1990;79(2):85-91 [2167037.001]
  • [Cites] Surg Today. 1992;22(3):265-8 [1392332.001]
  • [Cites] Virchows Arch. 1994;425(5):541-5 [7850080.001]
  • [Cites] Thorax. 1995 Nov;50(11):1225-6 [8553286.001]
  • [Cites] Obstet Gynecol. 1997 May;89(5 Pt 2):850-2 [9166348.001]
  • [Cites] Pathol Oncol Res. 1998;4(1):44-7 [9555121.001]
  • [Cites] Chest. 2000 Mar;117(3):921-2 [10713035.001]
  • (PMID = 17017666.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC3890720
  •  go-up   go-down


96. Gradowski JF, Mantha GS, Hunt JL, Dacic S: Molecular alterations in atypical adenomatous hyperplasia occurring in benign and cancer-bearing lungs. Diagn Mol Pathol; 2007 Jun;16(2):87-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular alterations in atypical adenomatous hyperplasia occurring in benign and cancer-bearing lungs.
  • Atypical adenomatous hyperplasia (AAH) is considered to be a precursor lesion of the lung adenocarcinoma.
  • Several genetic abnormalities have been reported in AAH associated with adenocarcinoma, but little is known about AAH associated with benign lung lesions.
  • To address this we compared the molecular characteristics of AAH present in benign conditions to those coexisting with carcinoma.
  • Seven cases of AAH from resected non-neoplastic lungs (AAH-B) and 12 cases from lungs resected for primary lung carcinoma (AAH-M) were analyzed for loss of heterozygosity (LOH) using 21 polymorphic microsatellite markers situated in proximity to known tumor suppressor genes on chromosomes 3p, 5q, 7p, 9p, 10q, and 17p.
  • Our results showed a significant overlap in LOH patterns between AAH with or without coexistent lung malignancy.
  • Therefore, AAH may represent a smoking induced low-grade neoplastic lesion that may be a precursor lesion of only a subset of invasive lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenomatosis, Pulmonary / genetics. Loss of Heterozygosity. Lung / pathology. Lung Neoplasms / genetics. Precancerous Conditions / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Genetic Markers / genetics. Humans. Male. Microsatellite Repeats. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525677.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers
  •  go-up   go-down


97. Zhang Y, Miao Y, Yi J, Wang R, Chen L: Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer. Clin Lung Cancer; 2010 Jul 1;11(4):264-70
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
  • BACKGROUND: Deleted in lung and esophageal cancer 1 (DLEC1) gene was a new candidate tumor suppressor gene.
  • We determined the expression level and methylation status of DLEC1 in non-small-cell lung cancer (NSCLC), and the DLEC1 methylation in plasma DNA as a biomarker for NSCLC was further evaluated.
  • PATIENTS AND METHODS: The study population enrolled 78 paired NSCLC specimens and adjacent normal tissues and 25 benign pulmonary lesions.
  • RESULTS: Hypermethylation of DLEC1 was found in 41% (32/78) of NSCLC tissues, which was significantly higher than that of adjacent normal tissues (3.8%; 3/78) and benign lesions (0/25; P < .001).
  • Methylated DLEC1 was detected in 35.9% (28/78) of plasma samples from NSCLC patients and only 2% (1/50) in cancer-free controls, and the concordance of DLEC1 methylation status in plasmas and corresponding tumor tissues was good.
  • CONCLUSION: DLEC1 is silenced by promoter methylation in NSCLC specimens and is widely expressed in adjacent normal tissues and benign control samples.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. DNA Methylation. Epigenesis, Genetic. Lung Neoplasms / genetics. Promoter Regions, Genetic / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Case-Control Studies. Female. Humans. Immunoenzyme Techniques. Lung / metabolism. Lung / pathology. Male. Middle Aged. Prognosis. Survival Rate. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20630829.001).
  • [ISSN] 1938-0690
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DLEC1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


98. Suzuki-Uematsu S, Shiraishi K, Ito T, Adachi N, Inage Y, Taeda Y, Ueki H, Ohtani H: Malignant phyllodes tumor composed almost exclusively of a fibrosarcomatous component: a case report and review of malignant phyllodes tumors with metastases. Breast Cancer; 2010 Jul;17(3):218-24
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant phyllodes tumor composed almost exclusively of a fibrosarcomatous component: a case report and review of malignant phyllodes tumors with metastases.
  • Here we present a case of malignant phyllodes tumor which was composed almost exclusively of a fibrosarcomatous component.
  • A 52-year-old Japanese female noted a rapid increase of her right breast tumor.
  • On admission, multiple lung metastases were detected by imaging.
  • The tumor, 10 x 10 cm in the largest dimension, had somewhat of a pushing margin, and showed a flesh-like appearance with marked necrosis.
  • Microscopically, the tumor showed proliferation of atypical ovoid- or spindle-shaped cells in a myxoid matrix.
  • Multiple sectioning revealed that the tumor had only focal occurrence of elongated tubular structures, and the occurrence of a small component of benign phyllodes tumor, leading to the aforementioned final diagnosis.
  • We reviewed 15 malignant phyllodes tumors with metastases reported in Japan.
  • [MeSH-major] Breast Neoplasms / pathology. Fibrosarcoma / pathology. Lung Neoplasms / secondary. Phyllodes Tumor / secondary

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19350353.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


99. Yamamoto Y, Nishiyama Y, Ishikawa S, Gotoh M, Bandoh S, Kanaji N, Asakura M, Ohkawa M: 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose. J Comput Assist Tomogr; 2008 May-Jun;32(3):432-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose.
  • OBJECTIVE: The purpose of this study was to evaluate the accuracy of 3'-deoxy-3'-F-fluorothymidine (FLT) positron emission tomography (PET) for detection of lung tumor in comparison with 2-deoxy-2-F-fluoro-D-glucose (FDG) PET.
  • METHODS: Fifty-four patients with newly diagnosed pulmonary nodules on chest computed tomographic (CT) scan suggestive of a malignant tumor were examined with both FLT and FDG PET.
  • The intensity of uptake in lung tumors was scored.
  • RESULTS: Thirty-six patients were found to have lung cancer; and 18, benign lesions.
  • Using visual analysis, the sensitivity of FLT PET for detection of lung cancer was 83%; the specificity, 83%; and the accuracy, 83%.
  • The uptake of FLT in lung cancer was significantly lower than that of FDG.
  • CONCLUSIONS: These preliminary results indicate that FLT PET may be specific for malignant tumors although uptake of FLT in lung cancer was significantly lower than that of FDG.
  • [MeSH-major] Dideoxynucleosides. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520552.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dideoxynucleosides; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


100. Liu L, Liao GQ, He P, Zhu H, Liu PH, Qu YM, Song XM, Xu QW, Gao Q, Zhang Y, Chen WF, Yin YH: Detection of circulating cancer cells in lung cancer patients with a panel of marker genes. Biochem Biophys Res Commun; 2008 Aug 8;372(4):756-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of circulating cancer cells in lung cancer patients with a panel of marker genes.
  • The current study was undertaken to examine the circulating cancer cells of lung cancer patients using a panel of markers and to evaluate the clinical significance of such tests.
  • Peripheral blood mononuclear cells (PBMCs) from 134 lung cancer patients, 106 benign pulmonary disease, and 80 healthy individuals were isolated and assessed by nested reverse transcription-PCR assay for the expression of three different tumor markers, including tumor specific antigen 9 (TSA-9), Keratin 19 (KRT-19), and Pre-progastrin-releasing peptide (Pre-proGRP).
  • Receiver operating characteristic curve (ROC) analysis showed that the combination of these markers was highly sensitive and specific in differentiating cancer patients from healthy and benign pulmonary disease controls.
  • Of the 134 lung cancer patient blood samples, 84.3% expressed at least one tumor marker.
  • Positivity of more than one marker predicted a poor response to therapy and short survival time in non-small cell lung cancer patients.
  • [MeSH-major] Biomarkers, Tumor / genetics. Lung Neoplasms / diagnosis. Neoplasm Proteins / genetics. Neoplastic Cells, Circulating
  • [MeSH-minor] Humans. Keratin-19 / genetics. Peptides / genetics. Prognosis. Protein Precursors / genetics. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18514066.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FAM83A protein, human; 0 / Keratin-19; 0 / Neoplasm Proteins; 0 / Peptides; 0 / Protein Precursors; 0 / RNA, Neoplasm; 0 / gastrin-releasing peptide precursor
  •  go-up   go-down






Advertisement